WO2001083460A1 - Composes cycliques - Google Patents
Composes cycliques Download PDFInfo
- Publication number
- WO2001083460A1 WO2001083460A1 PCT/JP2001/002034 JP0102034W WO0183460A1 WO 2001083460 A1 WO2001083460 A1 WO 2001083460A1 JP 0102034 W JP0102034 W JP 0102034W WO 0183460 A1 WO0183460 A1 WO 0183460A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- substituted
- optionally substituted
- hydroxyl
- lower alkoxy
- Prior art date
Links
- 150000001923 cyclic compounds Chemical class 0.000 title description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 607
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 255
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 195
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 125
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 115
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims abstract description 106
- 125000003282 alkyl amino group Chemical group 0.000 claims abstract description 96
- 125000003118 aryl group Chemical group 0.000 claims abstract description 41
- 150000003839 salts Chemical class 0.000 claims abstract description 36
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 16
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims abstract description 9
- -1 indanylamino group Chemical group 0.000 claims description 268
- 125000003277 amino group Chemical group 0.000 claims description 115
- 125000004076 pyridyl group Chemical group 0.000 claims description 69
- 125000003107 substituted aryl group Chemical group 0.000 claims description 69
- 229920006395 saturated elastomer Polymers 0.000 claims description 55
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 51
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 45
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 37
- 238000000034 method Methods 0.000 claims description 32
- 125000005843 halogen group Chemical group 0.000 claims description 28
- 125000002757 morpholinyl group Chemical group 0.000 claims description 28
- 125000006383 alkylpyridyl group Chemical group 0.000 claims description 17
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims description 15
- 125000002950 monocyclic group Chemical group 0.000 claims description 14
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 13
- 125000005936 piperidyl group Chemical group 0.000 claims description 13
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 11
- 201000001881 impotence Diseases 0.000 claims description 11
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 10
- 125000002619 bicyclic group Chemical group 0.000 claims description 10
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 10
- 125000002252 acyl group Chemical group 0.000 claims description 9
- 125000005530 alkylenedioxy group Chemical group 0.000 claims description 9
- 125000004043 oxo group Chemical group O=* 0.000 claims description 9
- 125000004429 atom Chemical group 0.000 claims description 7
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 6
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 6
- 125000004122 cyclic group Chemical group 0.000 claims description 6
- 125000002541 furyl group Chemical group 0.000 claims description 6
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
- 125000005236 alkanoylamino group Chemical group 0.000 claims description 4
- 125000005036 alkoxyphenyl group Chemical group 0.000 claims description 4
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical group 0.000 claims description 4
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 4
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 4
- 241001024304 Mino Species 0.000 claims description 3
- 125000005037 alkyl phenyl group Chemical group 0.000 claims description 3
- 125000006392 alkylpyrimidinyl group Chemical group 0.000 claims description 3
- 125000000304 alkynyl group Chemical group 0.000 claims description 3
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 claims description 3
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 125000004193 piperazinyl group Chemical group 0.000 claims description 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 3
- 206010051153 Diabetic gastroparesis Diseases 0.000 claims description 2
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 2
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000005942 tetrahydropyridyl group Chemical group 0.000 claims description 2
- 208000001647 Renal Insufficiency Diseases 0.000 claims 2
- 125000001589 carboacyl group Chemical group 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 201000006370 kidney failure Diseases 0.000 claims 2
- UBOOKRVGOBKDMM-UHFFFAOYSA-N 3h-imidazo[4,5-c]pyridine Chemical compound C1=NC=C2NC=NC2=C1 UBOOKRVGOBKDMM-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 claims 1
- 125000005879 dioxolanyl group Chemical group 0.000 claims 1
- 125000000686 lactone group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 7
- 239000003814 drug Substances 0.000 abstract description 6
- 125000001424 substituent group Chemical group 0.000 abstract description 6
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 3
- 230000004064 dysfunction Effects 0.000 abstract description 2
- 150000002596 lactones Chemical group 0.000 abstract description 2
- 230000003449 preventive effect Effects 0.000 abstract description 2
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 615
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 192
- 239000000203 mixture Substances 0.000 description 191
- 238000006243 chemical reaction Methods 0.000 description 180
- 239000002904 solvent Substances 0.000 description 180
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 179
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 165
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 162
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 155
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 153
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 153
- 239000000243 solution Substances 0.000 description 132
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical group [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 126
- 239000011541 reaction mixture Substances 0.000 description 126
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 121
- 230000002829 reductive effect Effects 0.000 description 117
- 238000002844 melting Methods 0.000 description 109
- 230000008018 melting Effects 0.000 description 109
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 105
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 93
- 239000012044 organic layer Substances 0.000 description 85
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 79
- 238000003756 stirring Methods 0.000 description 71
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 69
- 239000000284 extract Substances 0.000 description 64
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 63
- 229910000030 sodium bicarbonate Chemical group 0.000 description 62
- 235000017557 sodium bicarbonate Nutrition 0.000 description 62
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 60
- 238000010898 silica gel chromatography Methods 0.000 description 60
- 239000000843 powder Substances 0.000 description 57
- 239000007864 aqueous solution Substances 0.000 description 56
- 238000001816 cooling Methods 0.000 description 54
- 229920005989 resin Polymers 0.000 description 53
- 239000011347 resin Substances 0.000 description 53
- 238000001914 filtration Methods 0.000 description 48
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 47
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 45
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 43
- 229910052938 sodium sulfate Inorganic materials 0.000 description 40
- 235000011152 sodium sulphate Nutrition 0.000 description 40
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 39
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 39
- 239000000706 filtrate Substances 0.000 description 37
- 239000012267 brine Substances 0.000 description 36
- 239000000741 silica gel Substances 0.000 description 36
- 229910002027 silica gel Inorganic materials 0.000 description 36
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 36
- 239000010410 layer Substances 0.000 description 35
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 32
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 30
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 26
- 239000013078 crystal Substances 0.000 description 25
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical group [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 24
- 230000001590 oxidative effect Effects 0.000 description 24
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 23
- 239000002585 base Substances 0.000 description 22
- 235000019441 ethanol Nutrition 0.000 description 22
- 239000000725 suspension Substances 0.000 description 22
- 239000003795 chemical substances by application Substances 0.000 description 20
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 19
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 19
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 19
- 239000007787 solid Substances 0.000 description 19
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 18
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical group [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 18
- 238000012746 preparative thin layer chromatography Methods 0.000 description 18
- 239000007858 starting material Substances 0.000 description 18
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 17
- 238000004440 column chromatography Methods 0.000 description 17
- 239000002244 precipitate Substances 0.000 description 17
- 125000006239 protecting group Chemical group 0.000 description 17
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 16
- 238000001871 ion mobility spectroscopy Methods 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 15
- HVVNJUAVDAZWCB-YFKPBYRVSA-N [(2s)-pyrrolidin-2-yl]methanol Chemical compound OC[C@@H]1CCCN1 HVVNJUAVDAZWCB-YFKPBYRVSA-N 0.000 description 15
- 239000012046 mixed solvent Substances 0.000 description 15
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 15
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 14
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 description 14
- 239000011780 sodium chloride Substances 0.000 description 14
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical group [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 13
- 238000000668 atmospheric pressure chemical ionisation mass spectrometry Methods 0.000 description 13
- 239000003921 oil Substances 0.000 description 13
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 13
- 239000012312 sodium hydride Substances 0.000 description 13
- 229910000104 sodium hydride Inorganic materials 0.000 description 13
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 12
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 12
- 239000006260 foam Substances 0.000 description 12
- 229910000029 sodium carbonate Inorganic materials 0.000 description 12
- 235000017550 sodium carbonate Nutrition 0.000 description 12
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 11
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 11
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 11
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 11
- 239000002253 acid Substances 0.000 description 11
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 10
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 10
- 238000000354 decomposition reaction Methods 0.000 description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 10
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 10
- SHNUBALDGXWUJI-UHFFFAOYSA-N pyridin-2-ylmethanol Chemical compound OCC1=CC=CC=N1 SHNUBALDGXWUJI-UHFFFAOYSA-N 0.000 description 10
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 9
- 239000011259 mixed solution Substances 0.000 description 9
- 150000007530 organic bases Chemical class 0.000 description 9
- 229910000027 potassium carbonate Inorganic materials 0.000 description 9
- 235000011181 potassium carbonates Nutrition 0.000 description 9
- ROSKZJGILXBSFM-UHFFFAOYSA-N pyrimidin-2-ylmethanamine Chemical compound NCC1=NC=CC=N1 ROSKZJGILXBSFM-UHFFFAOYSA-N 0.000 description 9
- 238000010992 reflux Methods 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 229910052783 alkali metal Inorganic materials 0.000 description 8
- 239000003054 catalyst Substances 0.000 description 8
- 230000002140 halogenating effect Effects 0.000 description 8
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 7
- BTTNYQZNBZNDOR-UHFFFAOYSA-N 2,4-dichloropyrimidine Chemical compound ClC1=CC=NC(Cl)=N1 BTTNYQZNBZNDOR-UHFFFAOYSA-N 0.000 description 7
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 7
- 229910021529 ammonia Inorganic materials 0.000 description 7
- 239000001569 carbon dioxide Substances 0.000 description 7
- 229910002092 carbon dioxide Inorganic materials 0.000 description 7
- RBHJBMIOOPYDBQ-UHFFFAOYSA-N carbon dioxide;propan-2-one Chemical compound O=C=O.CC(C)=O RBHJBMIOOPYDBQ-UHFFFAOYSA-N 0.000 description 7
- 239000012141 concentrate Substances 0.000 description 7
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- 150000007529 inorganic bases Chemical group 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- YCCILVSKPBXVIP-UHFFFAOYSA-N 2-(4-hydroxyphenyl)ethanol Chemical compound OCCC1=CC=C(O)C=C1 YCCILVSKPBXVIP-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 229940043279 diisopropylamine Drugs 0.000 description 6
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 6
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- FOEMIZSFFWGXHX-UHFFFAOYSA-N 2-methylsulfanylpyrimidine Chemical compound CSC1=NC=CC=N1 FOEMIZSFFWGXHX-UHFFFAOYSA-N 0.000 description 5
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 5
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 235000011089 carbon dioxide Nutrition 0.000 description 5
- ZCDOYSPFYFSLEW-UHFFFAOYSA-N chromate(2-) Chemical compound [O-][Cr]([O-])(=O)=O ZCDOYSPFYFSLEW-UHFFFAOYSA-N 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000005457 ice water Substances 0.000 description 5
- 239000007800 oxidant agent Substances 0.000 description 5
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 5
- 125000006479 2-pyridyl methyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 4
- ANOUKFYBOAKOIR-UHFFFAOYSA-N 3,4-dimethoxyphenylethylamine Chemical compound COC1=CC=C(CCN)C=C1OC ANOUKFYBOAKOIR-UHFFFAOYSA-N 0.000 description 4
- YNJSNEKCXVFDKW-UHFFFAOYSA-N 3-(5-amino-1h-indol-3-yl)-2-azaniumylpropanoate Chemical compound C1=C(N)C=C2C(CC(N)C(O)=O)=CNC2=C1 YNJSNEKCXVFDKW-UHFFFAOYSA-N 0.000 description 4
- SWBUHQQTIPEPMK-UHFFFAOYSA-N 5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine Chemical compound C1NCCN2C=CN=C21 SWBUHQQTIPEPMK-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 description 4
- 239000003638 chemical reducing agent Substances 0.000 description 4
- WDCDAAMJNUHOIY-UHFFFAOYSA-N ethyl acetate;2-propan-2-yloxypropane Chemical compound CCOC(C)=O.CC(C)OC(C)C WDCDAAMJNUHOIY-UHFFFAOYSA-N 0.000 description 4
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 4
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 4
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 4
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 238000001665 trituration Methods 0.000 description 4
- OCNMSDZALRAYEX-UHFFFAOYSA-N (3-chloro-4-methoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C=C1Cl OCNMSDZALRAYEX-UHFFFAOYSA-N 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
- 125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- ODWXUNBKCRECNW-UHFFFAOYSA-M bromocopper(1+) Chemical compound Br[Cu+] ODWXUNBKCRECNW-UHFFFAOYSA-M 0.000 description 3
- 239000012230 colorless oil Substances 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 239000004744 fabric Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000005227 gel permeation chromatography Methods 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 3
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 229960003310 sildenafil Drugs 0.000 description 3
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 3
- CRWJEUDFKNYSBX-UHFFFAOYSA-N sodium;hypobromite Chemical compound [Na+].Br[O-] CRWJEUDFKNYSBX-UHFFFAOYSA-N 0.000 description 3
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- 239000003039 volatile agent Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- ZPQLRIBSXORPSO-UHFFFAOYSA-N (1-pyrimidin-2-ylpyrrolidin-2-yl)methanol Chemical compound OCC1CCCN1C1=NC=CC=N1 ZPQLRIBSXORPSO-UHFFFAOYSA-N 0.000 description 2
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 2
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N 1,1-dimethoxyethane Chemical compound COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 2
- FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical compound C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 description 2
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- 229940005561 1,4-benzoquinone Drugs 0.000 description 2
- ZDZHCHYQNPQSGG-UHFFFAOYSA-N 1-naphthalen-1-ylnaphthalene Chemical group C1=CC=C2C(C=3C4=CC=CC=C4C=CC=3)=CC=CC2=C1 ZDZHCHYQNPQSGG-UHFFFAOYSA-N 0.000 description 2
- DUIITDAJVYZQBP-UHFFFAOYSA-N 2-(methoxymethoxymethyl)pyrrolidine Chemical compound COCOCC1CCCN1 DUIITDAJVYZQBP-UHFFFAOYSA-N 0.000 description 2
- FVJPIFWJQUIPNO-UHFFFAOYSA-N 2-methylpropan-2-ol;oxolane Chemical compound CC(C)(C)O.C1CCOC1 FVJPIFWJQUIPNO-UHFFFAOYSA-N 0.000 description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- MWGZSNLLUOVUNK-UHFFFAOYSA-N 2-tritylsulfanylacetamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(SCC(=O)N)C1=CC=CC=C1 MWGZSNLLUOVUNK-UHFFFAOYSA-N 0.000 description 2
- QBUQQUOGXPOBAQ-UHFFFAOYSA-N 3,5-dibromo-1-oxidopyridin-1-ium Chemical compound [O-][N+]1=CC(Br)=CC(Br)=C1 QBUQQUOGXPOBAQ-UHFFFAOYSA-N 0.000 description 2
- DFOHHQRGDOQMKG-UHFFFAOYSA-N 4-chloro-2-methylsulfanylpyrimidine Chemical compound CSC1=NC=CC(Cl)=N1 DFOHHQRGDOQMKG-UHFFFAOYSA-N 0.000 description 2
- GXWNSJYVSIJRLS-UHFFFAOYSA-N 6-bromo-8-methylimidazo[1,2-a]pyrazine Chemical compound CC1=NC(Br)=CN2C=CN=C12 GXWNSJYVSIJRLS-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 125000005915 C6-C14 aryl group Chemical group 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 229920001367 Merrifield resin Polymers 0.000 description 2
- OPKOKAMJFNKNAS-UHFFFAOYSA-N N-methylethanolamine Chemical compound CNCCO OPKOKAMJFNKNAS-UHFFFAOYSA-N 0.000 description 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
- 235000011941 Tilia x europaea Nutrition 0.000 description 2
- MBXGFUHLCSNTHP-UHFFFAOYSA-N [1-(1,3-thiazol-2-yl)pyrrolidin-2-yl]methanol Chemical compound OCC1CCCN1C1=NC=CS1 MBXGFUHLCSNTHP-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 2
- 150000008041 alkali metal carbonates Chemical class 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 230000001548 androgenic effect Effects 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 238000010531 catalytic reduction reaction Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- UCDHYFZYUGDETN-UHFFFAOYSA-N cyanophosphonic acid Chemical compound OP(O)(=O)C#N UCDHYFZYUGDETN-UHFFFAOYSA-N 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- 125000006232 ethoxy propyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 2
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 2
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- JGJLWPGRMCADHB-UHFFFAOYSA-N hypobromite Chemical compound Br[O-] JGJLWPGRMCADHB-UHFFFAOYSA-N 0.000 description 2
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Chemical compound Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 description 2
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000004571 lime Substances 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 2
- 239000012053 oil suspension Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- JLTDJTHDQAWBAV-UHFFFAOYSA-N phenyldimethylamine Natural products CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 description 2
- 239000011736 potassium bicarbonate Substances 0.000 description 2
- HVVNJUAVDAZWCB-UHFFFAOYSA-N prolinol Chemical compound OCC1CCCN1 HVVNJUAVDAZWCB-UHFFFAOYSA-N 0.000 description 2
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000006462 rearrangement reaction Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- LEIMLDGFXIOXMT-UHFFFAOYSA-N trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- DITUWAKQAUNTDJ-UHFFFAOYSA-N (2,4-dichloropyrimidin-5-yl)-(3,4,5-trimethoxyphenyl)methanone Chemical compound COC1=C(OC)C(OC)=CC(C(=O)C=2C(=NC(Cl)=NC=2)Cl)=C1 DITUWAKQAUNTDJ-UHFFFAOYSA-N 0.000 description 1
- HIJWQWQFGJBUKU-UHFFFAOYSA-N (2,4-dichloropyrimidin-5-yl)-pyridin-2-ylmethanol Chemical compound C=1N=C(Cl)N=C(Cl)C=1C(O)C1=CC=CC=N1 HIJWQWQFGJBUKU-UHFFFAOYSA-N 0.000 description 1
- QPHLRCUCFDXGLY-UHFFFAOYSA-N (3,4,5-trimethoxyphenyl)methanol Chemical compound COC1=CC(CO)=CC(OC)=C1OC QPHLRCUCFDXGLY-UHFFFAOYSA-N 0.000 description 1
- IKWWOZCEHOYKAO-UHFFFAOYSA-N (3-chloro-4-methoxyphenyl)methanamine;hydrochloride Chemical compound Cl.COC1=CC=C(CN)C=C1Cl IKWWOZCEHOYKAO-UHFFFAOYSA-N 0.000 description 1
- TZHJVLGDHRXGDX-UHFFFAOYSA-N (3-chloro-4-methoxyphenyl)methanol Chemical compound COC1=CC=C(CO)C=C1Cl TZHJVLGDHRXGDX-UHFFFAOYSA-N 0.000 description 1
- GRRIMVWABNHKBX-UHFFFAOYSA-N (3-methoxyphenyl)methanamine Chemical compound COC1=CC=CC(CN)=C1 GRRIMVWABNHKBX-UHFFFAOYSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- QCEAVUKLTKCIOU-BTJKTKAUSA-N (z)-but-2-enedioic acid;pyrimidin-2-ylmethanamine Chemical compound NCC1=NC=CC=N1.OC(=O)\C=C/C(O)=O QCEAVUKLTKCIOU-BTJKTKAUSA-N 0.000 description 1
- MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical group C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 description 1
- PNHZYFXCSQLDHY-UHFFFAOYSA-N 1,2,3,5-tetrahydroimidazo[1,2-a]pyrazine Chemical compound C1C=NC=C2NCCN21 PNHZYFXCSQLDHY-UHFFFAOYSA-N 0.000 description 1
- 125000004530 1,2,4-triazinyl group Chemical group N1=NC(=NC=C1)* 0.000 description 1
- INLSCIDXDUXGTI-UHFFFAOYSA-N 1,2-dichloroethane;hydrochloride Chemical compound Cl.ClCCCl INLSCIDXDUXGTI-UHFFFAOYSA-N 0.000 description 1
- IDPURXSQCKYKIJ-UHFFFAOYSA-N 1-(4-methoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C=C1 IDPURXSQCKYKIJ-UHFFFAOYSA-N 0.000 description 1
- HYIVKFQALWGHOH-UHFFFAOYSA-N 1-chloro-2,6-dimethylhepta-2,5-dien-4-one Chemical compound ClCC(C)=CC(C=C(C)C)=O HYIVKFQALWGHOH-UHFFFAOYSA-N 0.000 description 1
- QGRPVMLBTFGQDQ-UHFFFAOYSA-N 1-chloro-2-methoxybenzene Chemical compound COC1=CC=CC=C1Cl QGRPVMLBTFGQDQ-UHFFFAOYSA-N 0.000 description 1
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 1
- GAHCTLWWQHFBHN-UHFFFAOYSA-N 1-methylsulfanyl-2h-pyrimidine Chemical compound CSN1CN=CC=C1 GAHCTLWWQHFBHN-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- RMPWFPSJMWDTAO-UHFFFAOYSA-N 1h-pyrimidin-2-ylidenemethanone Chemical compound O=C=C1NC=CC=N1 RMPWFPSJMWDTAO-UHFFFAOYSA-N 0.000 description 1
- VFYFMNCKPJDAPV-UHFFFAOYSA-N 2,2'-(5-oxo-1,3-dioxolan-4,4-diyl)diessigs Chemical compound C1N(C2)CN3CN1CN2C3.OC(=O)CC1(CC(O)=O)OCOC1=O VFYFMNCKPJDAPV-UHFFFAOYSA-N 0.000 description 1
- MYIPEPGIRJMNHF-UHFFFAOYSA-N 2,3,4-trimethyl-3-(2,3,4-trimethylpentan-3-yloxy)pentane Chemical compound CC(C)C(C)(C(C)C)OC(C)(C(C)C)C(C)C MYIPEPGIRJMNHF-UHFFFAOYSA-N 0.000 description 1
- SLMHHOVQRSSRCV-UHFFFAOYSA-N 2,3-dibromopyridine Chemical compound BrC1=CC=CN=C1Br SLMHHOVQRSSRCV-UHFFFAOYSA-N 0.000 description 1
- DPVIABCMTHHTGB-UHFFFAOYSA-N 2,4,6-trichloropyrimidine Chemical compound ClC1=CC(Cl)=NC(Cl)=N1 DPVIABCMTHHTGB-UHFFFAOYSA-N 0.000 description 1
- WYOSARQXNFQQIG-UHFFFAOYSA-N 2,4,6-trichloropyrimidine-5-carboxylic acid Chemical compound OC(=O)C1=C(Cl)N=C(Cl)N=C1Cl WYOSARQXNFQQIG-UHFFFAOYSA-N 0.000 description 1
- AJPKQSSFYHPYMH-UHFFFAOYSA-N 2,6-dichloropyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=C(Cl)N=C1Cl AJPKQSSFYHPYMH-UHFFFAOYSA-N 0.000 description 1
- NJWIMFZLESWFIM-UHFFFAOYSA-N 2-(chloromethyl)pyridine Chemical compound ClCC1=CC=CC=N1 NJWIMFZLESWFIM-UHFFFAOYSA-N 0.000 description 1
- PKZJLOCLABXVMC-UHFFFAOYSA-N 2-Methoxybenzaldehyde Chemical compound COC1=CC=CC=C1C=O PKZJLOCLABXVMC-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- WOXFMYVTSLAQMO-UHFFFAOYSA-N 2-Pyridinemethanamine Chemical compound NCC1=CC=CC=N1 WOXFMYVTSLAQMO-UHFFFAOYSA-N 0.000 description 1
- VWJSUNDGDBAUKI-UHFFFAOYSA-N 2-benzylsulfanyl-4-chloropyrimidine Chemical compound ClC1=CC=NC(SCC=2C=CC=CC=2)=N1 VWJSUNDGDBAUKI-UHFFFAOYSA-N 0.000 description 1
- ZFFBIQMNKOJDJE-UHFFFAOYSA-N 2-bromo-1,2-diphenylethanone Chemical compound C=1C=CC=CC=1C(Br)C(=O)C1=CC=CC=C1 ZFFBIQMNKOJDJE-UHFFFAOYSA-N 0.000 description 1
- JAXSPAXDDROBLQ-UHFFFAOYSA-N 2-chloro-4-(chloromethyl)-1-methoxybenzene Chemical compound COC1=CC=C(CCl)C=C1Cl JAXSPAXDDROBLQ-UHFFFAOYSA-N 0.000 description 1
- RHJIKEOGJDRTON-UHFFFAOYSA-N 2-chloro-4-[(3-chloro-4-methoxyphenyl)methylamino]pyridine-3-carboxylic acid Chemical compound C1=C(Cl)C(OC)=CC=C1CNC1=CC=NC(Cl)=C1C(O)=O RHJIKEOGJDRTON-UHFFFAOYSA-N 0.000 description 1
- UNCQVRBWJWWJBF-UHFFFAOYSA-N 2-chloropyrimidine Chemical compound ClC1=NC=CC=N1 UNCQVRBWJWWJBF-UHFFFAOYSA-N 0.000 description 1
- HBAHZZVIEFRTEY-UHFFFAOYSA-N 2-heptylcyclohex-2-en-1-one Chemical compound CCCCCCCC1=CCCCC1=O HBAHZZVIEFRTEY-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- PUYOAVGNCWPANW-UHFFFAOYSA-N 2-methylpropyl 4-aminobenzoate Chemical compound CC(C)COC(=O)C1=CC=C(N)C=C1 PUYOAVGNCWPANW-UHFFFAOYSA-N 0.000 description 1
- CUZKCNWZBXLAJX-UHFFFAOYSA-N 2-phenylmethoxyethanol Chemical compound OCCOCC1=CC=CC=C1 CUZKCNWZBXLAJX-UHFFFAOYSA-N 0.000 description 1
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
- JKSIXVZIFHKAPJ-UHFFFAOYSA-N 2h-benzotriazole;hydrate Chemical compound O.C1=CC=C2NN=NC2=C1 JKSIXVZIFHKAPJ-UHFFFAOYSA-N 0.000 description 1
- WMHGLLZEVOPGQD-UHFFFAOYSA-N 2h-pyridine-1-carbaldehyde Chemical compound O=CN1CC=CC=C1 WMHGLLZEVOPGQD-UHFFFAOYSA-N 0.000 description 1
- SOSPMXMEOFGPIM-UHFFFAOYSA-N 3,5-dibromopyridine Chemical compound BrC1=CN=CC(Br)=C1 SOSPMXMEOFGPIM-UHFFFAOYSA-N 0.000 description 1
- SAKUQCVNSVHPIW-UHFFFAOYSA-N 3,5-dibromopyridine-2-carbonitrile Chemical compound BrC1=CN=C(C#N)C(Br)=C1 SAKUQCVNSVHPIW-UHFFFAOYSA-N 0.000 description 1
- WVJHKVHTOLBDQI-UHFFFAOYSA-N 3,5-dichloropyrazine Chemical compound ClC1=C=NC=C(Cl)[N]1 WVJHKVHTOLBDQI-UHFFFAOYSA-N 0.000 description 1
- NYPYPOZNGOXYSU-UHFFFAOYSA-N 3-bromopyridine Chemical compound BrC1=CC=CN=C1 NYPYPOZNGOXYSU-UHFFFAOYSA-N 0.000 description 1
- ZYCYGNVKDLSNMY-UHFFFAOYSA-N 3-propan-2-yloxypentane Chemical compound CCC(CC)OC(C)C ZYCYGNVKDLSNMY-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- RNJOKCPFLQMDEC-UHFFFAOYSA-N 4(R),8-dimethyl-trans-2-nonenoyl-CoA Chemical compound COC(=O)CC(=O)CC(=O)OC RNJOKCPFLQMDEC-UHFFFAOYSA-N 0.000 description 1
- BRDCASUWCOWWIX-UHFFFAOYSA-N 4,5-dimethoxy-2-methylsulfanylpyrimidine Chemical compound COC1=CN=C(SC)N=C1OC BRDCASUWCOWWIX-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- WZNYBICPLIMKNV-UHFFFAOYSA-N 4-(aminomethyl)-2-chlorophenol Chemical compound NCC1=CC=C(O)C(Cl)=C1 WZNYBICPLIMKNV-UHFFFAOYSA-N 0.000 description 1
- 125000001999 4-Methoxybenzoyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C(*)=O 0.000 description 1
- PXYYGISXAWKTCT-UHFFFAOYSA-N 4-[(3-chloro-4-methoxyphenyl)methylamino]-2-methylsulfanylpyrimidine-5-carboxylic acid Chemical compound C1=C(Cl)C(OC)=CC=C1CNC1=NC(SC)=NC=C1C(O)=O PXYYGISXAWKTCT-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- GXCMABRXUXDVMW-UHFFFAOYSA-N 4-methoxy-2-methylsulfanylpyrimidine Chemical compound COC1=CC=NC(SC)=N1 GXCMABRXUXDVMW-UHFFFAOYSA-N 0.000 description 1
- QJMYXHKGEGNLED-UHFFFAOYSA-N 5-(2-hydroxyethylamino)-1h-pyrimidine-2,4-dione Chemical compound OCCNC1=CNC(=O)NC1=O QJMYXHKGEGNLED-UHFFFAOYSA-N 0.000 description 1
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- UNQYAAAWKOOBFQ-UHFFFAOYSA-N 7-[(4-chlorophenyl)methyl]-8-[4-chloro-3-(trifluoromethoxy)phenoxy]-1-(3-hydroxypropyl)-3-methylpurine-2,6-dione Chemical compound C=1C=C(Cl)C=CC=1CN1C=2C(=O)N(CCCO)C(=O)N(C)C=2N=C1OC1=CC=C(Cl)C(OC(F)(F)F)=C1 UNQYAAAWKOOBFQ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 229910015900 BF3 Inorganic materials 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 206010007556 Cardiac failure acute Diseases 0.000 description 1
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- 208000006992 Color Vision Defects Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- YIIMEMSDCNDGTB-UHFFFAOYSA-N Dimethylcarbamoyl chloride Chemical compound CN(C)C(Cl)=O YIIMEMSDCNDGTB-UHFFFAOYSA-N 0.000 description 1
- 206010057671 Female sexual dysfunction Diseases 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 241000219289 Silene Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 229910052776 Thorium Inorganic materials 0.000 description 1
- 102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 1
- 108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 1
- XAKBSHICSHRJCL-UHFFFAOYSA-N [CH2]C(=O)C1=CC=CC=C1 Chemical group [CH2]C(=O)C1=CC=CC=C1 XAKBSHICSHRJCL-UHFFFAOYSA-N 0.000 description 1
- DBJUEJCZPKMDPA-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O DBJUEJCZPKMDPA-UHFFFAOYSA-N 0.000 description 1
- WRYNUJYAXVDTCB-UHFFFAOYSA-M acetyloxymercury Chemical compound CC(=O)O[Hg] WRYNUJYAXVDTCB-UHFFFAOYSA-M 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 125000004171 alkoxy aryl group Chemical group 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 125000004647 alkyl sulfenyl group Chemical group 0.000 description 1
- 125000006398 alkylpyrazinyl group Chemical group 0.000 description 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- YCOXTKKNXUZSKD-UHFFFAOYSA-N as-o-xylenol Natural products CC1=CC=C(O)C=C1C YCOXTKKNXUZSKD-UHFFFAOYSA-N 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 238000010533 azeotropic distillation Methods 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- BJTNHGVCFWDNDP-LBPRGKRZSA-N benzyl (2s)-2-(hydroxymethyl)pyrrolidine-1-carboxylate Chemical compound OC[C@@H]1CCCN1C(=O)OCC1=CC=CC=C1 BJTNHGVCFWDNDP-LBPRGKRZSA-N 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- UENWRTRMUIOCKN-UHFFFAOYSA-N benzyl thiol Chemical compound SCC1=CC=CC=C1 UENWRTRMUIOCKN-UHFFFAOYSA-N 0.000 description 1
- XKXHCNPAFAXVRZ-UHFFFAOYSA-N benzylazanium;chloride Chemical compound [Cl-].[NH3+]CC1=CC=CC=C1 XKXHCNPAFAXVRZ-UHFFFAOYSA-N 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- HFNQLYDPNAZRCH-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O.OC(O)=O HFNQLYDPNAZRCH-UHFFFAOYSA-N 0.000 description 1
- JYYOBHFYCIDXHH-UHFFFAOYSA-N carbonic acid;hydrate Chemical compound O.OC(O)=O JYYOBHFYCIDXHH-UHFFFAOYSA-N 0.000 description 1
- VMPYZMFURVPIHK-UHFFFAOYSA-N carbononitridic isothiocyanate Chemical compound S=C=NC#N VMPYZMFURVPIHK-UHFFFAOYSA-N 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- BULLHNJGPPOUOX-UHFFFAOYSA-N chloroacetone Chemical compound CC(=O)CCl BULLHNJGPPOUOX-UHFFFAOYSA-N 0.000 description 1
- 125000002668 chloroacetyl group Chemical group ClCC(=O)* 0.000 description 1
- SKCNIGRBPJIUBQ-UHFFFAOYSA-N chloroform;ethyl acetate Chemical compound ClC(Cl)Cl.CCOC(C)=O SKCNIGRBPJIUBQ-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 201000007254 color blindness Diseases 0.000 description 1
- 230000004456 color vision Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- FXORZKOZOQWVMQ-UHFFFAOYSA-L dichloropalladium;triphenylphosphane Chemical compound Cl[Pd]Cl.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 FXORZKOZOQWVMQ-UHFFFAOYSA-L 0.000 description 1
- SOCTUWSJJQCPFX-UHFFFAOYSA-N dichromate(2-) Chemical compound [O-][Cr](=O)(=O)O[Cr]([O-])(=O)=O SOCTUWSJJQCPFX-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- VONWDASPFIQPDY-UHFFFAOYSA-N dimethyl methylphosphonate Chemical compound COP(C)(=O)OC VONWDASPFIQPDY-UHFFFAOYSA-N 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- OYJXTOVLKZDGFK-UHFFFAOYSA-N ethanol;2-propan-2-yloxypropane Chemical compound CCO.CC(C)OC(C)C OYJXTOVLKZDGFK-UHFFFAOYSA-N 0.000 description 1
- WLOQDGSMJNYRRC-UHFFFAOYSA-N ethyl 4-[(3-chloro-4-methoxyphenyl)methylamino]-2-methylsulfanylpyrimidine-5-carboxylate Chemical compound CCOC(=O)C1=CN=C(SC)N=C1NCC1=CC=C(OC)C(Cl)=C1 WLOQDGSMJNYRRC-UHFFFAOYSA-N 0.000 description 1
- QDHHLXABEXNRJX-UHFFFAOYSA-N ethyl 4-hydroxy-6-oxo-1h-pyridine-3-carboxylate Chemical compound CCOC(=O)C1=CNC(O)=CC1=O QDHHLXABEXNRJX-UHFFFAOYSA-N 0.000 description 1
- MVEAAGBEUOMFRX-UHFFFAOYSA-N ethyl acetate;hydrochloride Chemical compound Cl.CCOC(C)=O MVEAAGBEUOMFRX-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- CTIKAHQFRQTTAY-UHFFFAOYSA-N fluoro(trimethyl)silane Chemical compound C[Si](C)(C)F CTIKAHQFRQTTAY-UHFFFAOYSA-N 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- JYVHOGDBFNJNMR-UHFFFAOYSA-N hexane;hydrate Chemical compound O.CCCCCC JYVHOGDBFNJNMR-UHFFFAOYSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;n-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- SNHMUERNLJLMHN-UHFFFAOYSA-N iodobenzene Chemical compound IC1=CC=CC=C1 SNHMUERNLJLMHN-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
- 229940011051 isopropyl acetate Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- AFRJJFRNGGLMDW-UHFFFAOYSA-N lithium amide Chemical class [Li+].[NH2-] AFRJJFRNGGLMDW-UHFFFAOYSA-N 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- ANYSGBYRTLOUPO-UHFFFAOYSA-N lithium tetramethylpiperidide Chemical compound [Li]N1C(C)(C)CCCC1(C)C ANYSGBYRTLOUPO-UHFFFAOYSA-N 0.000 description 1
- MUERZYSPGYLGBT-UHFFFAOYSA-N lithium;molecular hydrogen Chemical compound [Li].[H][H] MUERZYSPGYLGBT-UHFFFAOYSA-N 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052751 metal Chemical class 0.000 description 1
- 239000002184 metal Chemical class 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- RHMQNXNXUZLEIY-UHFFFAOYSA-N methanol;2-propan-2-yloxypropane Chemical compound OC.CC(C)OC(C)C RHMQNXNXUZLEIY-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- OJURWUUOVGOHJZ-UHFFFAOYSA-N methyl 2-[(2-acetyloxyphenyl)methyl-[2-[(2-acetyloxyphenyl)methyl-(2-methoxy-2-oxoethyl)amino]ethyl]amino]acetate Chemical compound C=1C=CC=C(OC(C)=O)C=1CN(CC(=O)OC)CCN(CC(=O)OC)CC1=CC=CC=C1OC(C)=O OJURWUUOVGOHJZ-UHFFFAOYSA-N 0.000 description 1
- UTBCRHAMJFMIIR-UHFFFAOYSA-N methyl 3-chloro-3-oxopropanoate Chemical compound COC(=O)CC(Cl)=O UTBCRHAMJFMIIR-UHFFFAOYSA-N 0.000 description 1
- GLVNWYLAJDNOFS-UHFFFAOYSA-N methyl 4-benzylsulfanyl-2,6-dichloropyrimidine-5-carboxylate Chemical compound COC(=O)C1=C(Cl)N=C(Cl)N=C1SCC1=CC=CC=C1 GLVNWYLAJDNOFS-UHFFFAOYSA-N 0.000 description 1
- JWOSXVMUUBWGOL-UHFFFAOYSA-N methyl 4-chloro-2-nitrobenzoate Chemical compound COC(=O)C1=CC=C(Cl)C=C1[N+]([O-])=O JWOSXVMUUBWGOL-UHFFFAOYSA-N 0.000 description 1
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- CZFNISFYDPIDNM-UHFFFAOYSA-N n,n-dimethylformamide;oxolane Chemical compound CN(C)C=O.C1CCOC1 CZFNISFYDPIDNM-UHFFFAOYSA-N 0.000 description 1
- NTMHWRHEGDRTPD-UHFFFAOYSA-N n-(4-azidosulfonylphenyl)acetamide Chemical compound CC(=O)NC1=CC=C(S(=O)(=O)N=[N+]=[N-])C=C1 NTMHWRHEGDRTPD-UHFFFAOYSA-N 0.000 description 1
- XSIGKBGYHPTLBF-UHFFFAOYSA-N n-[(3-chlorophenyl)methyl]-1-(4-methoxyphenyl)methanamine Chemical compound C1=CC(OC)=CC=C1CNCC1=CC=CC(Cl)=C1 XSIGKBGYHPTLBF-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- SFJGCXYXEFWEBK-UHFFFAOYSA-N oxazepine Chemical compound O1C=CC=CC=N1 SFJGCXYXEFWEBK-UHFFFAOYSA-N 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- FHHJDRFHHWUPDG-UHFFFAOYSA-N peroxysulfuric acid Chemical compound OOS(O)(=O)=O FHHJDRFHHWUPDG-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 201000004240 prostatic hypertrophy Diseases 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- IDXKTTNFXPPXJY-UHFFFAOYSA-N pyrimidin-1-ium;chloride Chemical compound Cl.C1=CN=CN=C1 IDXKTTNFXPPXJY-UHFFFAOYSA-N 0.000 description 1
- HZGCZRCZOMANHK-UHFFFAOYSA-N pyrimidin-2-ylmethanol Chemical compound OCC1=NC=CC=N1 HZGCZRCZOMANHK-UHFFFAOYSA-N 0.000 description 1
- IIHQNAXFIODVDU-UHFFFAOYSA-N pyrimidine-2-carbonitrile Chemical compound N#CC1=NC=CC=N1 IIHQNAXFIODVDU-UHFFFAOYSA-N 0.000 description 1
- IIVUJUOJERNGQX-UHFFFAOYSA-N pyrimidine-5-carboxylic acid Chemical compound OC(=O)C1=CN=CN=C1 IIVUJUOJERNGQX-UHFFFAOYSA-N 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000004506 retinal light response Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 150000003385 sodium Chemical class 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- KKCBUQHMOMHUOY-UHFFFAOYSA-N sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 1
- 229910001948 sodium oxide Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- PAIRNPIFEFCXCR-UHFFFAOYSA-M sodium;ethyl acetate;hydroxide Chemical compound [OH-].[Na+].CCOC(C)=O PAIRNPIFEFCXCR-UHFFFAOYSA-M 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- ZHZOIVSXSKARMO-UHFFFAOYSA-N tert-butyl chlorate Chemical compound CC(C)(C)OCl(=O)=O ZHZOIVSXSKARMO-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 125000004665 trialkylsilyl group Chemical group 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- LZTRCELOJRDYMQ-UHFFFAOYSA-N triphenylmethanol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(O)C1=CC=CC=C1 LZTRCELOJRDYMQ-UHFFFAOYSA-N 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Definitions
- the present invention relates to a novel cyclic compound having a cGMP-specific phosphodiesterase (PDE) inhibitory activity (PDE V inhibitory activity) and useful as a medicament, and a method for producing the same.
- PDE cGMP-specific phosphodiesterase
- c GMP an intracellular second messenger
- phosphodiesterase which is widely distributed in tissues of the body
- ⁇ inhibition of the PDE activity increases the concentration of intracellular cGMP.
- various pharmacological actions such as vascular smooth muscle relaxing action, bronchial smooth muscle relaxing action, platelet, inhibitory action, etc., are expressed.
- PDE VP harmful activity include various diseases caused by dysfunction of cGMP signaling, such as hypertension, angina, and myocardial infarction. It is known to be useful in the treatment of chronic and acute heart failure, pulmonary hypertension (WO 96/05176, etc.), prostatic hypertrophy (Australia Patent Publication 9955977), and female sexual dysfunction [Vemulapalli et al. ⁇ Sciences, Vol. 67, pp. 23-29 (2000) (Life Sciences)], Diabetic gastroparesis [Watkins et al., Journal 'Oppoclinic Power' Investigation, Vol. 106, 373-384 (2000) (J. Clin. Invest.)], Acarassia [Bortolotti et al., Gas-entrance, Vol. 118, 253-257 (2000) (Gastroenterology);], diarrhea
- 4-methylbiperazine [generic name; sildenafil :) is useful for the treatment of diseases such as penile erectile dysfunction [Boolell et al. Jar "Nar Op'Perology Supplement, Vol. 155, No. 5, 495A, 739 (1996) (The Journal of Urology, Supplement) ⁇ Terrett et al., Bioorganic and Unmedical 'Chemistry 'Letters', Vol. 6, No. 15, pp.
- sildenafil has also been reported to have side effects such as headache, flushing, gastrointestinal tract disorders, rhinitis, color blindness and erectile dysfunction [Irwin et al., The New England Journal of Obv. Medicine, Vol. 338, No. 20, pp. 1397–1404 (1998) (The New England Journal of Medicine), Morales et al., Internationale Research Institute, Vol. 10, No. 2, pp. 69-73 (1998)
- the present invention is to provide a novel cyclic compound which has excellent phosphodiesterase V (PDE V) P and has a harmful effect and is useful as a preventive and therapeutic drug for penile erectile dysfunction with few side effects. Further, the present invention also provides a method for producing such a novel cyclic compound.
- PDE V phosphodiesterase V
- the present invention provides a compound represented by the general formula (I):
- R 1 is a lower alkoxy group which may be substituted, an amino group which may be substituted, a nitrogen-containing heterocyclic group which may be substituted, a nitrogen-containing heterocyclic group which may be substituted May be substituted with a hydroxyl group or a cyano group,
- R 2 is a lower alkylamino group optionally substituted with an optionally substituted aryl group, a lower alkoxy group substituted with an optionally substituted aryl group, a nitrogen-containing aromatic heterocyclic group-substituted lower group An alkoxy group, a lower alkylamino group substituted with an optionally substituted heterocyclic group, or an optionally substituted aryl group, a substituted amino group,
- R 3 is an optionally substituted aryl group, an optionally substituted nitrogen-containing heterocyclic group, an optionally substituted lower alkyl group, an optionally substituted lower alkoxy group, an optionally substituted An optionally substituted cyclo-lower alkoxy group, which may be substituted A nitrogen-containing heterocyclic group-substituted hydroxyl group, or an amino group which may be substituted,
- R 4 , R 5 , R 6 or R 7 is an optionally substituted aryl group, an optionally substituted nitrogen-containing heterocyclic group, an optionally substituted lower alkoxy group, or a substituted Represents a good amino group,
- R 4 , R 5 , R 6 or R 7 combine with R 3 to form a compound of the formula:
- R 2 is a monovalent methyl group substituted with an optionally substituted aryl group.
- a substituted amino group, and R 3 is an optionally substituted lower alkynole group, an optionally substituted nitrogen-containing heterocyclic group-substituted monoalkyl substituted lower alkyl group, An amino group mono-substituted with a nitrogen-containing heterocyclic group which may be optionally substituted, or an amino group mono-substituted with a cycloalkyl group which may be substituted.
- R 1 is an optionally substituted lower alkoxy group, an optionally substituted amino group, an optionally substituted, optionally substituted with a nitrogen-containing heterocyclic group, a hydroxyl group, or a cyano group. Represents a group.
- Examples of the ring represented by are a benzene ring and a 5- to 6-membered monocyclic nitrogen-containing heterocyclic group.
- 5- to 6-membered aromatic units such as thiazolyl, oxazolyl, pyridyl, pyrimidyl, pyridazinyl and 1,2,4-triazinyl And a cyclic nitrogen-containing heterocyclic group.
- Examples of the "optionally substituted lower alkoxy group" for R 1 include a cyclo lower alkyl group, a hydroxyl group, an optionally protected lower alkylamino group, a lower alkoxy group, a hydroxyl-substituted lower alkyl group, and an aryl group.
- Examples of the ⁇ optionally substituted amino group '' for R 1 include a hydroxyl group, a lower alkoxy group, a pyridyl group, a lower alkylamino group, a cyano group, a phenyl group, a lower alkoxy group and / or a halogen atom.
- a lower alkylamino group which may be substituted with 1 to 3 same or different groups selected from a phenyl group, an indanyl group and a hydroxyl-substituted lower alkyl group which may be substituted, or an indanylamino group.
- the nitrogen-containing heterocyclic group of the “optionally substituted nitrogen-containing heterocyclic group” for R 1 is preferably a 5- to 14- membered monocyclic or bicyclic nitrogen-containing heterocyclic group, more specifically Specific examples include a 5- to 6-membered monocyclic nitrogen-containing heterocyclic group and an 8- to 12-membered bicyclic nitrogen-containing heterocyclic group.
- a pyrrolidinyl group a piperazur 5- or 6-membered non-aromatic monocyclic nitrogen-containing heterocyclic group such as piperidyl group, 1H—2,3-dihydropyropyrro [3,4-b] pyridine-12-yl group , 5,6,7,8-tetrahydroimidazo [1,2-a] pyrazine-17-yl group, 5,6,7,8-tetrahydro-1,7-naphthyridine-17-yl group and the like 8- to 10-membered bicyclic nitrogen-containing heterocyclic group in which a 5- to 6-membered aromatic monocyclic nitrogen-containing heterocyclic group is fused to a 5- to 6-membered non-aromatic monocyclic nitrogen-containing heterocyclic group Is mentioned.
- nitrogen-containing heterocyclic groups include a hydroxyl group, a protected amino group, a lower alkyl group, a lower alkoxy group, a lower alkoxycarbonyl group, a hydroxyl-substituted lower alkyl group, an oxo group, a pyridyl group, and a pyrimidinyl group.
- 1 to 4 groups selected from a benzylamino group substituted with a group and a benzylamino group substituted with a halogen atom on the benzene ring may be substituted.
- Examples of the “hydroxyl group optionally substituted with an optionally substituted nitrogen-containing heterocyclic group” for R 1 include a nitrogen-containing heterocyclic group selected from a piperidyl group, a lower alkylpiperidyl group, and a pyridyl group. And a hydroxyl group which may be substituted with a group.
- Examples of the aryl group in the “optionally substituted aryl group” for R 2 include a 5- to 10-membered monocyclic or bicyclic aromatic hydrocarbon group, and specific examples include a phenyl group, And a naphthyl group.
- aryl group which may be substituted in the case of "a lower alkylamino group which may be substituted with an aryl group which may be substituted", a lower alkoxy group, a halogen atom, protection Optionally protected amino group, hydroxyl group, lower alkoxypyridyl group, optionally protected lower alkylamino group, nitro group, halogen atom-substituted lower alkyl group, lower alkylenedioxy group, cyano group, protected And a lower alkylsulfonyl group or a lower alkylsulfenyl group, which may be substituted with a hydroxyl group, and may be substituted with 1 to 4 identical or different groups selected from these.
- aryl group may be the same or different selected from a lower alkoxy group, a halogen atom and a cyano group. It may be substituted with 1 to 4 groups.
- Examples of the “nitrogen-containing aromatic heterocyclic group-substituted lower alkoxy group” for R 2 include, for example, 1 to 3 identical or different nitrogen-containing aromatic heterocycles selected from a pyridyl group, a pyrimidinyl group and a pyrazur group. Examples include lower alkoxy groups substituted with a formula group.
- optionally substituted with optionally substituted heterocyclic group lower alkyl amino group represented by R 2, for example Indoriru group, pyrimidinyl group, benzofuranyl group, dihydro base Nzofuraniru group, a lower alkyl pyrimidinyl group, dihydrobenzo
- R 2 for example Indoriru group, pyrimidinyl group, benzofuranyl group, dihydro base Nzofuraniru group, a lower alkyl pyrimidinyl group, dihydrobenzo
- 1 to 4 substituted or heterocyclic group-substituted lower alkylamino groups selected from oxazolyl groups and dihydrobenzoimidazolyl groups Is mentioned.
- aryl group As the “optionally substituted aryl group” for R 3 , an aryl group or an aryl group which may be substituted with 1 to 4 identical or different groups selected from a lower alkoxy group and a lower alkylamino group And aryl groups which may be substituted with one to two lower alkylenedioxy groups.
- aryl group include a 5- to 10-membered monocyclic or bicyclic aromatic hydrocarbon group, and specific examples include a phenyl group and a naphthyl group.
- Examples of the nitrogen-containing heterocyclic group in the “optionally substituted nitrogen-containing heterocyclic group” for R 3 include a 5- to 6-membered monocyclic nitrogen-containing heterocyclic group. Is a 5- to 6-membered non-aromatic monocyclic nitrogen-containing heterocyclic group such as a piperidyl group, a piperazuryl group or a morpholinyl group; And an aromatic monocyclic nitrogen-containing heterocyclic group.
- the nitrogen-containing cyclic group is substituted with 1 to 4 identical or different groups selected from lower alkyl groups, hydroxyl groups, amino groups, chlorosulfinyloxy groups, and piperidyloxysulfinyl / reoxy groups. May be.
- the ⁇ lower alkyl group which may be substituted '' represented by R 3 is the same or different one to three groups selected from a morpholinyl group, a pyridyl group, a lower alkylsulfonyl group and a di-lower alkoxyphosphoryl group.
- An optionally substituted lower alkyl group is exemplified.
- R 3 there may be mentioned a pyridyl group, a lower alkoxypyridyl group, a pyrimidinyl group, a lower alkylamino group, a pyrazur group, and a lower group optionally substituted with a phenyl group.
- Alkoxy group pyrimigel group-substituted oxy group, pyridyl group-substituted oxy group, pyrimidyl-substituted lower alkoxy group, morpholinyl group, lower alkylmorpholinyl group, N-lower alkyl-N-pyrimidieramino group, It may be substituted with 1 to 3 identical or different groups selected from di-lower alkyldioxolanyl groups, lower alkoxy-lower alkoxy groups, pyridylcarponylamino groups, hydroxyl groups, piperidyl groups and lower alkylpiperidyl groups! /, Lower alkoxy groups.
- cyclo-lower alkoxy group for example, a lower-mouth alkoxy group which may be substituted with a hydroxyl group is exemplified.
- ⁇ optionally substituted nitrogen-containing heterocyclic group-substituted hydroxyl group '' for R 3 for example, the same or different 1 to 4 groups selected from a pyrimigel group and a cyano group-substituted lower alkyl group And a nitrogen-containing heterocyclic group-substituted hydroxyl group.
- Examples of the “optionally substituted amino group” for R 3 include (i) a lower alkoxy group optionally substituted with a lower alkoxy group, (ii) a cyano group, a hydroxyl group, a lower alkoxy group, and a lower alkoxy group.
- Phenyl, carbamoyl, lower anolyalkylamino, pyridyl, lower alkylpyridyl, lower alkoxypyridyl, pyrimidinyl, lower alkoxypyrimidi which may be substituted with Ninole group, morpholyl group, lower alkylmorpholinyl group, hydroxyl-substituted lower alkylmorpholinyl group, cyano lower alkylmorpholinyl group, hydroxyl group piperidyl group, oxo-substituted piperazinyl group, lower alkylpiperazinyl Group, lower alkylsulfurpiperazyl group, pyrrolidinyl group, lower alkyl A lower group which may be substituted with 1 to 3 same or different groups selected from a dinyl group, a lower alkylpyrazul group, a tetrahydrofuranyl group, a lower alkoxyphenoxy group, a lower alkoxypyri
- morpholinyl group and (ix) morpholinyl group, (x) lower alkoxycarbonyl group, lower alkylsulfonyl group, lower alkyl group, cyano lower An alkyl group, a hydroxyl-substituted lower alkanoyl group, a formyl group, a lower alkoxy lower alkanoyl group, and a lower alkylamino lower alkanoyl group, and a piperidyl group which may be substituted with the same or different 1 to 4 groups selected from a lower alkyl group; (xi) an optionally protected hydroxy group, a lower alkoxy group or a pyrimidinyl group, a cyclo lower alkyl group optionally substituted with 1 to 3 same or different groups selected from substituted oxy groups, and ( x ii) lower alkyl groups and lower A pyrimidinylamino group optionally substituted with a lower alkoxycarboel, and an amino
- Examples of the protecting group for the amino group, lower alkylamino group, and hydroxyl group include a forminole group and a lower alkanoyl group.
- a phenyl group which may be substituted with a lower alkoxy group a ⁇ nitrogen-containing heterocyclic group which may be substituted ''
- the ⁇ cyclic group '' includes a hydroxyl group, a lower alkyl group, or a hydroxyl-substituted nitrogen-containing heterocyclic group which may be substituted with a lower alkyl group
- the ⁇ nitrogen-containing heterocyclic group '' includes 5- to 14-membered Monocyclic or bicyclic nitrogen-containing heterocyclic group, more specifically, a 5- to 6-membered monocyclic nitrogen-containing heterocyclic group and an 8- to 12-membered bicyclic nitrogen-containing heterocyclic group
- a 5- to 6-membered non-aromatic monocyclic nitrogen-containing heterocyclic group such as a pyrrolidnole group, a piperazinyl group,
- a lower alkoxy group As the “optionally substituted lower alkoxy group J", a lower alkoxy group; as the “optionally substituted amino group”, a nitrogen-containing heterocyclic group-substituted lower anoalkyl group, a hydroxyl-substituted lower alkyl group or be substituted by a lower alkyl group include an amino group, also bonded to each other with R 3, wherein:
- the case includes a plurality of substituents (for example, in the case of a lower alkylamino group, a mono- or di-lower alkylamino group is included. )
- a lower alkyl group refers to methyl, ethyl, propyl, It means a linear or branched alkyl group having 1 to 6 carbon atoms, such as pill, butyl, isobutyl, tert-butyl and the like.
- the lower alkoxy group means a straight-chain or branched-chain alkoxy group having 1 to 6 carbon atoms such as methoxy, ethoxy, propoxy, isopropyloxy, butyloxy, isobutyloxy, tert-butyloxy and the like.
- the lower alkanol group means a linear or branched alkanoyl group having 2 to 7 carbon atoms such as acetyl, propionyl, and butyryl.
- the cycloalkyl group means cycloalkyl having 3 to 8 carbon atoms, such as cyclopropynole, cyclopentinole, cyclopentinole, cyclohexyl /, cycloheptyl /, and the like.
- the lower alkylene group means a linear or branched alkylene group having 1 to 6 carbon atoms such as methylene, ethylene and trimethylene.
- the aryl group means a monocyclic, bicyclic or tricyclic 6-14 membered aryl group (which may be partially saturated) such as a phenyl group, a naphthyl group, an indolyl group and an indaninole group.
- the nitrogen-containing heterocyclic group means a monocyclic or bicyclic 5- to 14-membered nitrogen-containing heterocyclic group.
- R 1 is substituted with an optionally substituted lower alkoxy group, an optionally substituted amino group, an optionally substituted nitrogen-containing heterocyclic group, an optionally substituted nitrogen-containing heterocyclic group A hydroxyl group or a cyano group which may be
- R 2 is a lower alkylamino group optionally substituted with an optionally substituted aryl group, a lower alkoxy group substituted with an optionally substituted aryl group, a nitrogen-containing aromatic heterocyclic group-substituted lower An alkoxy group, a lower alkylamino group substituted with an optionally substituted heterocyclic group, or an optionally substituted aryl group A substituted amino group,
- R 3 is an optionally substituted aryl group, an optionally substituted nitrogen-containing heterocyclic group, an optionally substituted lower alkyl group, an optionally substituted lower alkoxy group, or an optionally substituted An optionally substituted cyclo-lower alkoxy group, an optionally substituted nitrogen-containing heterocyclic group-substituted hydroxyl group, or an optionally substituted amino group, wherein R 4 , R 5 , R 6 or R 7 is substituted An optionally substituted aryl group, an optionally substituted V-nitrogen-containing heterocyclic group, an optionally substituted lower alkoxy group or an optionally substituted amino group,
- R 4 , R 5 , R 6 , or R 7 combine with R 3 to form:
- R 2 is an amino group mono-substituted with a methyl group substituted with an optionally substituted aryl group
- R 3 is an optionally substituted lower alkyl group, an optionally substituted nitrogen-containing heterocyclic group, an amino group mono-substituted with a substituted lower alkyl group, an optionally substituted nitrogen-containing heterocyclic group
- an amino group mono-substituted with a group or an amino group mono-substituted with an optionally substituted cycloalkyl group
- R 1 is a lower alkoxy group which may be substituted, an amino group which may be substituted, a hydroxyl group which may be substituted by a nitrogen-containing heterocyclic group which may be substituted, or a cyano group. Certain compounds are mentioned.
- Y represents the formula:-NH-,-NR 4 -,-S-or-0-,
- R 1 is a lower alkoxy group which may be substituted, an amino group which may be substituted A nitrogen-containing heterocyclic group which may be substituted, a hydroxyl group which may be substituted by a nitrogen-containing heterocyclic group which may be substituted, or a cyano group,
- R 2 is a lower alkylamino group optionally substituted with an optionally substituted aryl group, a lower alkoxy group substituted with an optionally substituted aryl group, a nitrogen-containing aromatic heterocyclic group-substituted lower group An alkoxy group, a lower alkylamino group substituted with an optionally substituted heterocyclic group, or an optionally substituted aryl group-substituted amino group;
- R 3 is an optionally substituted aryl group, an optionally substituted nitrogen-containing heterocyclic group, an optionally substituted lower alkyl group, an optionally substituted lower alkoxy group, an optionally substituted An optionally substituted cyclo-lower alkoxy group, an optionally substituted nitrogen-containing heterocyclic group-substituted hydroxyl group, or an optionally substituted amino group
- R 4 is an optionally substituted aryl group, An optionally substituted nitrogen-containing heterocyclic group, an optionally substituted lower alkoxy group, or an optionally substituted amino group
- R 4 combines with R 3 to form a compound of the formula:
- R 1 is a lower alkoxy group which may be substituted, an amino group which may be substituted, a nitrogen-containing heterocyclic group which may be substituted, a nitrogen-containing heterocyclic group which may be substituted A hydroxyl group or a cyano group, which may be substituted with a cyclic group,
- R 2 may be substituted with an optionally substituted aryl group, a lower alkylamino group, a lower alkoxy group substituted with an optionally substituted aryl group, a nitrogen-containing aromatic heterocyclic group A substituted lower alkoxy group, a lower alkylamino group substituted with an optionally substituted heterocyclic group, or an optionally substituted aryl group-substituted amino group;
- R 3 is an optionally substituted aryl group, an optionally substituted nitrogen-containing heterocyclic group, an optionally substituted lower alkyl group, an optionally substituted lower alkoxy group, an optionally substituted An optionally substituted cyclo-lower alkoxy group, an optionally substituted nitrogen-containing heterocyclic group-substituted hydroxyl group, or an optionally substituted amino group, wherein R 5 , R 6 or R 7 may be substituted A good aryl group, a nitrogen-containing heterocyclic group which may be substituted, a lower alkoxy group which may be substituted, or an amino group which may be substituted;
- R 5 , R 6 , or R 7 combine with R 3 to form a compound of the formula:
- R 1 is substituted with an optionally substituted lower alkoxy group, an optionally substituted amino group, an optionally substituted nitrogen-containing heterocyclic group, an optionally substituted nitrogen-containing heterocyclic group.
- a hydroxyl group or a cyano group which may be
- R 2 is a lower alkylamino group which may be substituted with an aryl group which may be substituted, a lower alkoxy group which is substituted with an aryl group which may be substituted, or a nitrogen-containing aromatic heterocyclic group; A lower alkoxy group, a lower alkylamino group substituted with an optionally substituted heterocyclic group, or an optionally substituted aryl group A substituted amino group,
- R 3 is an optionally substituted aryl group, an optionally substituted nitrogen-containing heterocyclic group, an optionally substituted lower alkyl group, an optionally substituted lower alkoxy group, an optionally substituted An optionally substituted cyclo-lower alkoxy group, an optionally substituted nitrogen-containing heterocyclic group-substituted hydroxyl group, or an optionally substituted amino group,
- R 2 is an amino group mono-substituted with a methyl group substituted with an optionally substituted aryl group
- R 3 is an optionally substituted lower alkyl group, an optionally substituted nitrogen-containing heterocyclic group, an amino group mono-substituted with a substituted lower alkyl group, an optionally substituted nitrogen-containing heterocyclic group
- an amino group mono-substituted with a group or an amino group mono-substituted with an optionally substituted cycloalkyl group
- R 1 is a lower alkoxy group which may be substituted, an amino group which may be substituted, a hydroxyl group which may be substituted by a nitrogen-containing heterocyclic group which may be substituted, or a cyano group. Certain products may be mentioned.
- R 1 is substituted with an optionally substituted lower alkoxy group, an optionally substituted amino group, an optionally substituted nitrogen-containing heterocyclic group, an optionally substituted nitrogen-containing heterocyclic group Or a hydroxyl or cyano group,
- R 2 is a lower alkylamino group optionally substituted with an optionally substituted aryl group, a lower alkoxy group substituted with an optionally substituted aryl group, a nitrogen-containing aromatic heterocyclic group-substituted lower An alkoxy group, a lower alkylamino group substituted with a substituted or unsubstituted heterocyclic group, or an aryl group optionally substituted A substituted amino group,
- R 3 is an optionally substituted aryl group, an optionally substituted nitrogen-containing heterocyclic group, an optionally substituted lower alkyl group, an optionally substituted lower alkoxy group, or an optionally substituted An optionally substituted cyclo-lower alkoxy group, an optionally substituted nitrogen-containing heterocyclic group-substituted hydroxyl group, or an optionally substituted amino group, wherein R 5 , R 6 or R 7 may be substituted A good aryl group, a nitrogen-containing heterocyclic group which may be substituted, a lower alkoxy group which may be substituted, or an amino group which may be substituted;
- R 5 , R ⁇ or R 7 combine with R 3 to form a compound of the formula:
- R 1 is substituted with an optionally substituted lower alkoxy group, an optionally substituted amino group, an optionally substituted nitrogen-containing heterocyclic group, an optionally substituted nitrogen-containing heterocyclic group Or a hydroxyl or cyano group,
- R 2 may be substituted with an optionally substituted aryl group V, a lower alkylamino group, a lower alkoxy group substituted with an optionally substituted aryl group, a nitrogen-containing aromatic heterocyclic group A substituted lower alkoxy group, a lower alkylamino group substituted with an optionally substituted heterocyclic group, or an optionally substituted aryl group-substituted amino group;
- R 3 is an optionally substituted aryl group, an optionally substituted nitrogen-containing heterocyclic group, an optionally substituted lower alkyl group, an optionally substituted lower alkoxy group, or an optionally substituted An optionally substituted cyclo-lower alkoxy group, an optionally substituted nitrogen-containing heterocyclic group-substituted hydroxyl group, or an optionally substituted amino group.
- hydroxyl group a lower alkyl group, a lower alkoxy group, a hydroxyl-substituted lower alkyl group, an oxo group, a pyridyl group optionally substituted with a hydroxyl-substituted lower alkyl group, a pyrimidinyl group optionally substituted with a lower alkylamino group, Formyl group, mesyl group, optionally protected V, hydroxyl-substituted lower alkanoyl group and carbamoyl group
- Nitrogen-containing heterocyclic ring which may be substituted with 1 to 4 same or different groups selected from lower alkyl group, hydroxyl group, amino group, chlorosulfinyloxy group and piperidyloxysulfieroxy group.
- a piperidyl group which may be substituted with 1 to 4 identical or different groups selected from a pyrimidinyl group, a lower alkyl group and a cyano group-substituted lower alkyl group; Hydroxy group, or
- a cyano group a hydroxyl group, a lower alkoxy group, a phenyl group optionally substituted with a lower alkoxy group and / or a halogen atom, a carbamoyl group, a lower alkylamino group, a pyridyl group, a lower alkylpyridyl group, and a lower alkoxy group Pyridyl group, pyrimigel group, lower alkoxypyrimidinyl group, morpholinyl group, lower alkylmorpholinyl group, hydroxyl-substituted lower alkylmorpholinyl group, cyano-lower alkylmorpholinyl group, hydroxyl-substituted piperidyl group, oxo-substituted pyridyl group Ladur group, lower alkylpyriduryl group, lower alkylsulfonylbiperazinyl group, pyrrolidyl group,
- (Viii) selected from a lower alkoxycarbonyl group, a lower alkylsulfonyl group, a lower alkyl group, a cyano lower alkyl group, a hydroxyl-substituted lower alkanol group, a formyl group, a lower alkoxy lower alkyl group and a lower alkylamino lower alkyl group Piberidinyl group which may be substituted with the same or different 1 to 4 groups,
- (X) a pyrimigenoleamino group optionally substituted with a lower alkyl group and a lower alkoxycarbonyl group, Power et al same or different 1-2 amino amino group which may be substituted with a group selected, R 4, R 5, R 6 or R 7 is
- R 3 is bonded to each other to form:
- Y is the formula: -S-,
- R 1 is a pyrrolidinyl group optionally substituted with a hydroxyl-substituted lower alkyl group
- R 2 is a phenyl optionally substituted with 1 to 2 identical or different groups selected from a lower alkoxy group and a nitrogen atom V, lower alkylamino group
- R 3 is a lower alkoxy group or an amino group optionally substituted with a pyrimidinyl-substituted lower alkyl group.
- R 1 is (1) a lower alkoxy group which may be substituted with a lower alkylamino group or a pyridyl group, (2) a diamino group which may be substituted with a hydroxyl group or a lower alkoxy group, (3) a hydroxyl group, a lower group Substituted with an alkoxy group, a lower alkyl group, a hydroxyl-substituted lower alkyl group, an oxo group, a pyridyl group optionally substituted with a hydroxyl-substituted lower alkyl group, or a pyrimidinyl group optionally substituted with a lower alkylamino group; A nitrogen-containing heterocyclic group which may be substituted, or (4) a hydroxyl group which may be substituted with a pyridyl group,
- R 2 is a lower alkylamino group which may be substituted with a lower anoreoxy group and a phenyl group which may be substituted with Z or a halogen atom,
- R 3 is (1) a lower alkoxy group which may be substituted with a lower alkoxy group substituted with a phenyl group, or (2) (i) a lower alkoxy group, a pyridyl group, a lower alkylpyridyl group, a pyrimigel group, A lower alkyl group which may be substituted with the same or different group selected from a lower alkoxypyrimidyl group, a morpholinyl group and a lower alkylpyrazinyl group, (ii) pyridyl which may be substituted with a lower alkyl group Or (iii) an amino group optionally substituted with a cyclo-lower alkyl group optionally substituted with a hydroxyl group,
- R 5 , R 6 or R 7 is
- Rataton ring may the other to form represented, c that include compounds Among the compounds (I) of the present invention, preferred compounds are those represented by the general formula (I):
- cyclo-lower alkyl group hydroxyl group, optionally protected lower alkylamino group, lower alkylamino group, lower alkoxy group, hydroxyl-substituted lower alkyl group, phenyl group, lower alkoxyphenyl group, hydroxyl-substituted lower alkyl group 1 to 3 identical or different groups selected from an enyl group, a furyl group, a pyridyl group, a lower alkoxypyridyl group, a hydroxyl-substituted lower alkylpyridyl group, a lower alkylpyridyl group, a pyrimidinyl group, a lower alkoxypyrimidinyl group and a morpholinyl group
- a lower alkoxy group which may be substituted with
- hydroxyl group a lower alkyl group, a lower alkoxy group, a hydroxyl-substituted lower alkyl group, an oxo group, a pyridyl group optionally substituted with a hydroxyl-substituted lower alkyl group, a pyrimidinyl group optionally substituted with a lower alkylamino group , A formyl group, a mesyl group, a protected group, a hydroxyl-substituted lower alkyl group, and a substituted / unsubstituted / rebamoyl group.
- Nitrogen complex a hydroxyl group, a lower alkyl group, a lower alkoxy group, a hydroxyl-substituted lower alkyl group, an oxo group, a pyridyl group optionally substituted with a hydroxyl-substituted lower alkyl group, a pyrimidinyl group optionally
- a substituted or unsubstituted aryl group which may be substituted with 1 to 4 same or different groups selected from a hydroxyl-substituted lower alkyl group, a lower alkylsulfonyl group and a lower alkylsulfinyl group.
- aryl group which may be substituted with 1 to 4 same or different groups selected from lower alkoxy groups and lower alkylamino groups, or with 1 to 2 lower alkylenedioxy groups.
- Aryl group may be substituted with 1 to 4 same or different groups selected from lower alkoxy groups and lower alkylamino groups, or with 1 to 2 lower alkylenedioxy groups.
- pyridyl group lower alkoxypyridyl group, pyrimidinyl group, lower alkylamino group, pyrazur group, lower alkoxy group optionally substituted by phenyl group, pyrimidininole substituted oxy group, pyridyl substituted oxy group, pyrimigel substituted Lower alkoxy group, morpholinyl group, lower alkylmorpholinyl group, N-lower alkyl-1-N-pyrimidylamino group, lower alkyl dioxolael group, lower alkoxy lower alkoxy group, pyridinolecarbonyla A lower alkoxy group substituted with 1 to 3 same or different groups selected from a mino group, a hydroxyl group, and a lower alkylpiperidyl group,
- lower alkyl group or cyano group-substituted lower alkyl group A selected piperidyl group-substituted hydroxyl group which may be substituted with the same or different 1 to 4 groups, or
- amino group optionally substituted with one or two identical or different groups selected from the group consisting of:
- R 1 is a pyrrolidinyl group optionally substituted with a hydroxyl-substituted lower alkyl group
- R 2 is a lower alkoxy group Oyohi Soso same selected from androgenic atom or different 1-2 substituents which do also be substituted with good phenyl group optionally may be lower alk Kiruamino group group,
- R 3 is substituted with (1) a lower alkoxy group, (2) a lower alkyl group optionally substituted with a pyrimidininole group or a morpholinyl group, or (3) a cyclo lower alkyl group which may be substituted with a hydroxyl group. And an amino group which may be substituted.
- R 1 is a pyrrolidinyl group optionally substituted with a pyridyl group-substituted lower alkoxy group or a hydroxyl-substituted lower alkyl group,
- R 2 is a lower alkoxy group
- Contact Yopi Nono same selected from androgenic atom or different 1-2 substituents which do also be substituted with good phenyl group optionally may be lower alk Kiruamino group group,
- R 3 is (1) a lower alkoxy group, or (2) a lower alkyl group optionally substituted with a pyrimidinyl group or a morpholinyl group.
- preferred compounds are those represented by the general formula (I):
- the aryl group on RR 2 , R 3 , R 4 , R 5 , R 6 or R 7 is a monocyclic, bicyclic or tricyclic 6-14 membered aryl group (which may be partially saturated);
- the compound wherein the nitrogen-containing heterocyclic group on R 1 R 3 , R 4 , R 5 , R 6 or R 7 is a monocyclic or bicyclic 5- to 14-membered nitrogen-containing heterocyclic group.
- R ⁇ R 2 , R 3 , RR 5 , R 6 or R 7 mono-, bi- or tricyclic 6- to 14-membered arylene groups (which may be partially saturated) are feninole Group, a naphthinole group, an indenyl / le group, or an indani / le group.
- R 3 R 4 , R 5, R 6 or a monocyclic or bicyclic nitrogen-containing heterocyclic group 5-14 membered on R 7 has the formula: and,
- R ⁇ R 3, R 4, R 5, R 6 or a monocyclic or bicyclic 5-14 membered nitrogen-containing heterocyclic group on R 7 is a pyridyl group, a pyrimidinyl group, Imidazoriru group, piperazinyl Lysyl group, pyrazolyl group, morpholinyl group, pyriduryl group, pyrrolidinyl group, dihydroisoindolinole group, tetrahydroimidazo [1, 2-a] pyrazinole group, tetrahydrido isoquinolyl group, dihydro-5H-pyro mouth [3, 4-b] Pyridyl group, naphthyridyl group, pyrazo [3,4-d] pyridyl group, tetrahydropyridyl group, oxazolo [4,5-c] pyridyl group, octahydropyrido [3,4-d] pyrimi
- the compound of the present invention (I) or a pharmaceutically acceptable salt thereof has an excellent selective PDE V inhibitory action, and has little effect on color vision and blood pressure. Can be used for treatment.
- the compound (I) of the present invention can be used in a free form or in the form of a pharmaceutically acceptable salt for pharmaceutical use.
- Pharmaceutically acceptable salts of compound (I) include, for example, inorganic acid salts such as hydrochloride, sulfate, nitrate or hydrobromide, acetate, fumarate, oxalate, citrate And organic acid salts such as methanesulfonate, benzenesulfonate, tosylate and maleate.
- the compound (I) or a salt thereof of the present invention includes any of its inner salts and adducts, solvates and hydrates thereof.
- the compound (I) of the present invention or a pharmaceutically acceptable salt thereof can be used as a conventional pharmaceutical preparation. These pharmaceutical preparations are prepared by formulating them together with pharmaceutically acceptable excipients, binders, wetting agents, disintegrants, bulking agents, and other additives in a conventional manner.
- the dose of the compound (I) of the present invention or a pharmaceutically acceptable salt thereof varies depending on the administration method, age of the patient, body weight and condition, but is usually about 0.001 to 10 Omg per day. / kg, particularly preferably about 0.1 to 1 Omg /.
- compound (I) can be produced by the following [Method A] to [Method D].
- the compound (I) of the present invention has the general formula (II):
- X 1 represents a halogen atom
- R 8 represents a carboxyl-protecting group
- R 9 represents a substituted or lower alkyl group or an optionally substituted aryl group, and other symbols Has the same meaning as above
- the compound (I) of the present invention is obtained by halogenating the compound (VIII) to obtain a compound represented by the general formula (X):
- the compound can also be produced by reacting the compound with the compound (VI).
- the compound (I) of the present invention has the general formula (XVI) obtained by reducing the compound (IV)
- the group R 3 may be a lower alkoxy-substituted ethyl group.
- a compound having a morpholino group-substituted ethyl group that is, a compound represented by the general formula (Ia)
- R 10 represents a lower alkoxy group or a morpholino group, and other symbols have the same meanings as described above.
- the compound (I) of the present invention has a general formula (XXV) obtained by removing the carboxyl-protecting group R 8 of the ligate compound (IV):
- the compound (XXVI) can be obtained by reacting the compound (XVII) with the compound (IX) or a reactive derivative thereof, represented by the general formula (XXVIII):
- the compound (I) of the present invention comprises a dihalogeno compound (XI) and a compound represented by the general formula (XXIX):
- the compound can be produced by reacting the compound (VI) or a salt thereof.
- the compound (XXXII) is obtained by reacting the compound (XXX) with the compound (III) to obtain a compound of the general formula (XXXIII):
- R 13 represents a hydroxyl-protecting group or an amino-protecting group
- the compound (Ib) of the present invention is obtained by reacting the compound (XXXVI) with the compound (XL) to obtain a compound represented by the general formula (XLI):
- R 17 is an optionally substituted aryl group, and other symbols have the same meanings as described above.
- X 14 is a halogen atom, and other symbols have the same meanings as described above.
- the compound (Id) of the present invention has the general formula (XLVIII):
- Y 21 has the formula: represents X 8, X 9 1Q, x 7, X 8, X 9 and x 1Q is a halogen atom and the other symbols are the same ⁇
- R 5 ⁇ 7 represent R 5, R 6 or R 7)
- R 3 of compound (LIII) of the present invention may be converted after appropriately protecting the carboxyl group of compound (L).
- a commonly used solid phase carrier such as a resin may be used.
- the addition of compound (LII) can be appropriately performed.
- the compound (Id) of the present invention has the general formula (LIV):
- the compound (LV) is acted on by the compound (LII) and then the compound (VI) is acted on, or the compound (LV) is acted on by the compound (VI) and then acted on by the compound (LII) It can also be manufactured by the following.
- the compound (Id) of the present invention has the general formula (LVIII):
- a compound of formula (LX) obtained by reacting compound (LV I) with compound (IX) or a compound (IX) or a reactive derivative thereof, (Wherein the symbols have the same meanings as described above)
- Y is a compound represented by the formula: one NH—, one NR 4 —, one S— or one O—,
- R 2 is a compound represented by a lower alkylamino group which may be substituted by an optionally substituted aryl group, that is, a compound represented by the following general formula (I-e):
- the compound (Ie) of the present invention has the general formula (LXII):
- R 14 represents a protecting group, and other symbols have the same meanings as described above.
- R 16 represents an optionally substituted lower alkyl group or an optionally substituted aryl group, and other symbols have the same meanings as described above.
- compound (I) can also be produced by appropriately combining the respective steps in the above-mentioned production method.
- R 1 is appropriately changed. It may be replaced.
- the reaction between compound (II) and compound (III) can be carried out in a solvent in the presence or absence of a deoxidizing agent.
- a deoxidizing agent include organic bases such as N, N-diisopropylethylamine, N-methylmorpholine, triethylamine, and pyridine; and inorganic base groups such as sodium hydride, sodium carbonate, potassium carbonate, and sodium hydrogencarbonate. Etc. can be suitably used.
- Solvents include dimethyl sulfoxide, tetrahydrofuran, tonolen, ethinole acetate, chlorohonolem, dimethoxetane, and Any solvent that does not inhibit the reaction, such as silene, N, N-dimethylformamide, acetonitrile, N-methylpyrrolidone, N, N-dimethylacetoamide, dioxane, can be suitably used.
- the reaction between the compound (II) and the compound (III) having low reactivity suitably proceeds by adding a copper reagent such as copper bromide as a catalyst.
- the present reaction suitably proceeds at 110 ° C to room temperature, particularly preferably at 0 ° C to room temperature.
- the reaction of oxidizing compound (IV) to give compound (V) can be carried out in a solvent in the presence of an oxidizing agent.
- the oxidizing agent include peracids such as m-chloroperbenzoic acid and peracetic acid, manganese dioxide, sodium periodate, hydrogen peroxide, nitrous oxide, nitrogen, hydroperoxide, iodobenzene, and hypochlorite.
- Inorganic oxidizing agents such as tert-butyl chlorate, sulfuryl chloride and peroxymonosulfuric acid rim can be suitably used.
- a solvent that does not inhibit the reaction such as chloroform, methylene chloride, dichloroethane, and acetic acid, can be used as appropriate.
- the present reaction suitably proceeds at a temperature of from 170 to 50 ° C, especially from 110 to 10 ° C.
- the reaction between compound (V) and compound (VI) or a salt thereof can be carried out in a solvent in the presence or absence of a deoxidizing agent.
- a deoxidizing agent include organic bases such as ⁇ , ⁇ -diisopropylethylamine, ⁇ -methylmorpholine, triethylamine, and pyridine; and inorganic bases such as sodium hydride, sodium carbonate, potassium carbonate, cesium carbonate, and sodium hydrogencarbonate. It can be suitably used.
- an alkali metal salt such as a sodium salt and a potassium salt can be suitably used.
- Solvents such as ⁇ ⁇ , ⁇ -dimethylformamide, tetrahydrofuran, dimethoxyethane, dimethylsulfoxide, acetonitrile, ⁇ -methylpyrrolidone, ⁇ , ⁇ -dimethylacetamide, dioxane, diglyme, dimethoxyethane, etc. Can be suitably used. Further, the reaction between the compound (V) and the compound (VI) having low reactivity suitably proceeds by adding a zero-valent palladium catalyst and a phosphorus ligand.
- Trisdibenzylideneacetone dipalladium can be suitably used as a catalyst, and 2,2′-bisdiphenylphosphino 1,1,1′-binaphthyl can be suitably used as a phosphorus ligand.
- This reaction suitably proceeds at 0 to 250 ° C, particularly at room temperature to 200 ° C.
- the solvent water or a mixed solvent of water with methanol, ethanol, tetrahydrofuran, dioxane, N, N-dimethylhonolemamide, dimethyl sulfoxide, or the like can be used as appropriate.
- the present reaction suitably proceeds at 0 to 80 ° C, particularly 5 to 60 ° C.
- the protecting group R 8 for the carbonyl group a generally used protecting group for a carboxyl group such as a lower alkyl group and a benzyl group can be used.
- reaction between compound (VIII) and compound (IX) or a reactive derivative thereof can be carried out in a suitable solvent in the presence or absence of a condensing agent, a base or an activating agent.
- a condensing agent a condensing agent
- a halide or a metal salt of the compound (IX) can be suitably used.
- the condensing agent dicyclohexylcarpoimide, 1-ethyl-3- (3-dimethylaminopropyl) carpoimide, diphenylphosphoryl azide, and getyl cyanophosphonate, which are generally used in peptide synthesis, are preferably used. Can be.
- an organic base such as triethylamine or N-methylmorpholine can be suitably used, and as the activator, 1-hydroxybenzotriazole or the like can be suitably used.
- the solvent any solvent that does not inhibit the reaction, such as methylene chloride, tetrahydrofuran, N, N-dimethylformamide, acetonitrile, N, N-dimethylacetoamide, and ethyl acetate, can be suitably used. .
- the present reaction suitably proceeds at 130 to 50 ° C, particularly preferably at 10 to 10 ° C.
- compound (IX) or a reactive derivative thereof is reacted by first reacting compound (VIII) with an activator by a conventional method. Is reacted with a halogenating agent in the presence or absence of to give compound (X), and then to react with compound (IX).
- the reaction of compound (VIII) with a halogenating agent can be carried out in a solvent or without a solvent.
- the halogenating agent for example, Nyl chloride, oxalyl chloride, phosphorus pentachloride and the like can be suitably used.
- an amide compound such as ⁇ , ⁇ -dimethylformamide, getyl aniline or the like can be suitably used.
- the solvent any solvent that does not hinder the reaction, such as methylene chloride, chloroform, tetrahydrofuran, benzene, toluene and dioxane, can be suitably used.
- the present reaction suitably proceeds at 130 to 100 ° C, particularly 5 to 10 ° C.
- the subsequent reaction with compound (IX) can be carried out in a solvent in the presence of a deoxidizing agent.
- a deoxidizing agent examples include organic bases such as ⁇ , ⁇ -diisopropylethylamine, ⁇ -methylmonoleforin, triethynoleamine, pyridine, dimethylaminopyridine, sodium hydride, sodium carbonate, potassium carbonate, hydrogencarbonate, and the like.
- An inorganic base such as sodium can be suitably used.
- any solvent that does not inhibit the reaction such as tetrahydrofuran, methylene chloride, chlorophonorem, ⁇ , dimethinoleacetamide, tonolen, benzene, dioxane, and ethyl acetate, can be suitably used.
- This reaction suitably proceeds at 130 to; L 0 ° C, particularly 5 to L 0 ° C.
- the reaction of treating the dihalogeno compound (XI) with carbon dioxide to obtain the compound (XII) can be carried out in a solvent in the presence of a base.
- a basic alkali metal salt such as lithium diisopropylamide and lithium 2,2,6,6-tetramethylpiperidide can be preferably used.
- a solvent that does not inhibit the reaction such as tetrahydrofuran, 1,2-dimethoxyethane, and getyl ether, can be used as appropriate.
- the present reaction suitably proceeds at a temperature of 100 ° C. to 130 ° C., particularly preferably a temperature of 100 ° C. to 170 ° C.
- the reaction for protecting the carbonyl group of compound (XII) to give compound (XIII) can be carried out by a conventional method.
- the protecting group is a lower alkyl group
- the presence of a base group and a solvent The reaction can be carried out by reacting with an alkylating agent.
- an alkylating agent a lower alkyl nitride such as methyl iodide can be suitably used.
- the base an alkali metal bicarbonate such as sodium bicarbonate can be suitably used
- a solvent which does not inhibit the reaction such as N, N-dimethylformamide, tetrahydrofuran, can be suitably used.
- the present reaction suitably proceeds at 0 ° C to 100 ° C, particularly at room temperature to 70 ° C.
- the reaction of reacting compound (XIII) with compound (III) to obtain compound (XIV) can be carried out in the same manner as in the reaction of compound (II) with compound (III).
- reaction of reacting compound (XIV) with compound (VI) to give compound (VII) can be carried out in the same manner as in the reaction of compound (V) with compound (VI).
- the reaction of hydrolyzing compound (V) to give compound (XV) can be carried out in a solvent in the presence of a base.
- a base alkali metal hydroxides such as sodium hydroxide, lithium hydroxide, lithium hydroxide and the like, and alkali metal carbonates such as sodium carbonate and potassium carbonate can be suitably used.
- the solvent water or a mixed solvent of methanol, ethanol, tetrahydrofuran, dioxane, ⁇ , ⁇ -dimethylformamide, dimethylsulfoxide and the like and water can be used as appropriate.
- the present reaction suitably proceeds at 120 to 80 ° C, particularly 5 to 60 ° C.
- reaction of halogenating compound (XV) to obtain compound (XIV) can be carried out in the same manner as the reaction of halogenating compound (VIII) with a halogenating agent to obtain compound (X).
- the reaction for reducing compound (IV) to give compound (XVI) can be carried out in a suitable solvent in the presence of a reducing agent.
- a reducing agent an alkali metal aluminum hydride such as aluminum lithium hydrogen hydride, an alkali metal borohydride such as lithium hydrogen hydride, or the like can be preferably used.
- the solvent a solvent that does not inhibit the reaction, such as tetrahydrofuran, dioxane, getyl ether, and dimethoxyethane, can be suitably used. This reaction suitably proceeds at a temperature of from 178 ° C to the boiling point of the solvent used, particularly from 110 ° C to room temperature.
- the reaction of oxidizing compound (XVI) to give compound (XVII) can be carried out in a solvent in the presence of an oxidizing agent.
- the oxidizing agent is not particularly limited as long as it can induce alcohol to the corresponding carbonyl compound. Examples thereof include manganese dioxide, barium permanganate, potassium permanganate, 2,3-dichloromethane, 6-dicyano-1,4-benzoquinone, pyridinum chromate chromate, pyridinum dichromate and the like can be preferably used.
- Solvents include chlorohonolem, toluene, ethyl acetate, 1,2-dichloroethane, methylene chloride, tetrahydrofuran, etc. W
- a solvent that does not inhibit the reaction can be used as appropriate. This reaction suitably proceeds at 0 ° C to 100 ° C (particularly, room temperature to 70 ° C).
- reaction of oxidizing compound (XVII) to give compound (XVIII) can be carried out in the same manner as the reaction of oxidizing compound (IV) to give compound (V).
- reaction of reacting compound (XVIII) with compound (VI) to give compound (XIX) can be carried out in the same manner as in the reaction of compound (V) with compound (VI).
- reaction leading to compound (XX) by reacting compound (IX) with compound (IX) or a reactive derivative thereof can be carried out in a suitable solvent.
- a solvent such as tetrahydrofuran, dioxane, dimethyl ether, dimethoxyethane, or the like that does not inhibit the reaction can be used as appropriate.
- This reaction suitably proceeds at 178 ° C to room temperature.
- reaction of oxidizing compound (XX) to give compound (I) can be carried out in the same manner as the reaction of oxidizing compound (XVI) to give compound (XVII).
- the reaction between compound (XIX) and Grignard compound (XXI) can be carried out in a suitable solvent.
- a suitable solvent tetrahydrofuran, dioxane, methyl ether and the like can be suitably used.
- the present reaction suitably proceeds at a temperature of 178 ° C to 60 ° C, in particular, a temperature of 178 ° C to room temperature.
- the reaction for converting the compound (XXII) to a compound (XXIII) can be carried out in the same manner as the reaction for oxidizing the compound (XVI) to a compound (XVII).
- Reacting the compound ( ⁇ ) in R 1 Q is to obtain by reacting a compound morpholino group (XXIV)
- Compound R 1 0 is a morpholino group (I- a), the presence of a base or absence, appropriate It can be carried out in a suitable solvent.
- a base organic bases such as N, N-diisopropylethylamine, N-methylmorpholine, triethylamine, pyridine, and the like, and inorganic bases such as sodium hydride, sodium carbonate, carbonated carbonate, and sodium hydrogencarbonate are preferably used. Can be.
- any of ethanol, N, N-dimethinoleformamide, tetrahydrofuran, dimethoxyethane, dimethinole sulfoxide and the like can be suitably used.
- the present reaction suitably proceeds at 0 to 150 ° C, particularly at room temperature to 60 ° C.
- compound (XXIII) is reacted with compound (0OQV) where R 1 () is a lower alkoxy group.
- the reaction leading to the compound (Ia) in which R 1 G is a lower alkoxy group can be carried out in the presence of an acid, without solvent or in a suitable solvent.
- an acid an inorganic acid such as sulfuric acid and an organic acid such as methanesulfonic acid, camphorsulfonic acid, toluenesulfonic acid, and benzenesulfonic acid can be suitably used.
- any of ethyl ether, toluene, benzene, N, N-dimethylformamide, dimethoxyethane, dimethylsulfoxide and the like can be suitably used.
- the present reaction suitably proceeds at 0 to: L 50 ° C, particularly at room temperature to 60 ° C.
- the reaction for elimination of the protecting group R 8 of the lipoxyl group of the compound (IV) to obtain the compound (XXV) is similar to the reaction for removing the protecting group R 8 of the lipoxyl group of the compound (VII) to obtain the compound (VIII). Can be implemented.
- reaction leading to compound (XXVI) by reacting compound (XXV) with compound (IX) or a reactive derivative thereof can be carried out in the same manner as in the reaction of compound (VIII) with compound (IX) or a reactive derivative thereof. it can.
- reaction of oxidizing compound (XXVI) to give compound (XXVII) can be carried out in the same manner as the reaction of oxidizing compound (IV) to give compound (V).
- reaction of reacting compound (XXVII) with compound (VI) to give compound (I) of the present invention can be carried out in the same manner as in the reaction of compound (V) with compound (VI).
- reaction of compound (XVII) with compound (IX) or a reactive derivative thereof to lead to compound (XXVIII) is carried out in the same manner as in the reaction of compound (XIX) with compound (IX) or a reactive derivative thereof. can do.
- reaction for converting the compound (XXVIII) to a compound (XXVI) can be carried out in the same manner as the reaction for converting the compound (XVI) to a compound (XVII).
- the reaction of reacting compound (XI) with compound (XXIX) to give compound (XXX) can be carried out in a suitable solvent in the presence of a base.
- a base alkali metal salts of organic bases such as lithium diisopropylamide and lithium 2,2,6,6-tetramethinolebiperidide can be suitably used.
- Solvents such as tetrahydrofuran, 1,2-dimethoxyethane, and dimethyl ether which do not hinder the reaction Medium can be suitable.
- the present reaction suitably proceeds at 100 ° C. to 130 ° C., particularly preferably at 100 ° C. to 170 ° C.
- reaction of oxidizing compound (XXX) to give compound (XXXI) can be carried out in the same manner as the reaction of oxidizing compound (XVI) to give compound (XVII).
- reaction of reacting compound (XXXI) with compound (III) to give compound (XXXII) can be carried out in the same manner as in the reaction of compound (II) with compound (III).
- reaction of reacting compound (XXXII) with compound (VI) or a salt thereof to lead to compound (I) of the present invention can be carried out in the same manner as in the reaction of compound (V) with compound (VI).
- reaction of reacting compound (XXX) with compound (III) to give compound (XXXIII) can be carried out in the same manner as in the reaction of compound (II) with compound (III).
- reaction of oxidizing the compound (XXXIII) to give the compound (XXXII) can be carried out in the same manner as the reaction of oxidizing the compound (XVI) to give the compound (XVII).
- reaction leading to compound (XXXV) by reacting compound (XXXIV) with angmoyua can be carried out by reacting ammonia in a solvent in the presence of a condensing agent.
- Ammonia can be used as water or a solution.
- a condensing agent used in ordinary peptide synthesis for example, dicyclohexylcarboimide, 1-ethyl-13_ (3-dimethylaminopropyl) carpoimide, diisopropylpropyldiimide is preferably used. be able to.
- a solvent that does not inhibit the reaction such as N, N-dimethylformamide, methylene chloride, chlorohonolem, and tetrahydrofuran, can be suitably used.
- the present reaction suitably proceeds at a temperature of from 30 ° C to 50 ° C, especially from 0 ° C to room temperature.
- the reaction leading to the compound (XXXVI) by subjecting the compound (XXXV) to a Hoffman rearrangement reaction can be carried out by reacting an alkali metal hypoperogenate in a solvent in the presence of a base.
- a base sodium hydroxide, potassium hydroxide or the like is preferably used, and as the solvent, a solvent which does not inhibit the reaction such as dioxane, tetrahydrofuran, methylene chloride, acetonitrile, tert-butanol, methanol, ethanol and the like is suitably used.
- Hypochlorous acid is a hypochlorous acid alkali metal salt.
- Sodium, sodium hypobromite, hypobromite power rim, hypochlorite ring power, etc. can be preferably used.
- the present reaction suitably proceeds at a temperature of from 120 ° C to 100 ° C, especially from 10 ° C to 60 ° C.
- reaction for deprotecting compound (XXXVI) to give compound (XXXVII) or the reaction for deprotecting compound (XLI) to give compound (XLII) is based on the deprotection reaction commonly used for amino or hydroxyl protecting groups. It can be implemented by using.
- amino- or hydroxyl-protecting group examples include a honoleminole group, an alkanoinole group (such as an acetyl group, a propionyl group, and a chloroacetyl group), an aroyl group (such as a benzoynole group and a 4-methoxybenzoyl group), and an alkoxyl group.
- a binole group (a methoxycarbonyl group, a tert-butoxycarbonyl group, etc.), a trialkylsilyl group (a trimethylsilinole group, a tert-butyldimethylsilyl group, etc.), an arylalkoxycarbonyl group (a benzyloxycarbonyl group, etc.), An arylalkyl group (benzyl group, 4-methoxybenzinole group, etc.) and a tetrahydrovinyl group.
- Examples of the deprotection reaction of amino or hydroxyl protecting groups include, for example, acids (hydrochloric acid, sulfuric acid, phosphoric acid, p-toluenesulfonic acid, trifluoroacetic acid, acetic acid, hydrofluoric acid, hydrogen bromide, aluminum chloride, iodine) Hydrolysis or reduction with trimethylsilyl fluoride, boron trifluoride, etc.) or a base (sodium hydroxide, hydroxylated lime, carbonated lime, sodium carbonate, potassium bicarbonate, sodium bicarbonate, ammonia, hydrazine, etc.) Hydrogen-palladium carbon, formic acid-palladium carbon, zinc-acetic acid, metallic sodium-liquid ammonia, etc.), oxidation (2,3-dichloro-5,6-dicyanor 1,4-benzoquinone (DDQ), hydrogen peroxide, mercury acetate Etc.).
- acids hydrochloric acid, sulfuric acid, phosphoric
- the reaction between compound (XXXVII) and compound ( ⁇ ) can be carried out in a solvent in the presence of a deoxidizing agent (base).
- deoxidizing agents include sodium hydrogen hydride, potassium tert-butoxide, potassium carbonate, sodium carbonate, cesium carbonate, potassium hydroxide, sodium hydroxide, sodium methoxide, sodium ethoxide, potassium amide, and lithium diisopropylamide.
- Inorganic bases such as lithium amides and the like, or organic bases such as N, N-diisopropylamine, N-methylmorpholine, triethylamine and pyridine can be suitably used.
- Solvents include tetrahydrofuran, ethanol, methanol ⁇ ⁇ , dimethoxetane, dimethylformamid Solvents that do not inhibit the reaction, such as toluene, xylene, dimethyl sulfoxide, dimethylacetamide, and dioxane, can be suitably used. This reaction suitably proceeds at ⁇ 50 to the boiling point of the solvent used, particularly at 0 to 100 ° C.
- reaction between compound (XLIII) and compound (VI) can be carried out in the same manner as in the reaction between compound (V) and compound (VI).
- the reduction reaction of compound (XLIV) can be carried out by a conventional method, and can be suitably carried out, for example, by catalytic reduction.
- the catalytic reduction can be carried out, for example, by adding a catalyst in a solvent under a normal pressure of hydrogen.
- a catalyst to be used for example, palladium monocarbon can be suitably used.
- the solvent for example, ethanol can be suitably used. This reaction suitably proceeds at room temperature.
- the reaction between compound (XLV) and compound (XLVI) can be carried out in a solvent in the presence of a reducing agent and in the presence or absence of an acid.
- a reducing agent sodium triacyloxyborohydride such as triacetoxyborohydride can be suitably used.
- Organic acids such as acetic acid and propionic acid can be suitably used as the acid.
- the solvent any solvent that does not inhibit the reaction, such as dichloroethane, salt ⁇ : methylene, and tetrahydrofuran, can be suitably used.
- the reaction is carried out at a temperature of 150 ° C. to 100 ° C., especially 110 ° C. Properly proceeds at C to room temperature.
- the elimination of the protecting group R 8 of the lipoxyl group of the compound (XLVII) can be carried out in the same manner as the elimination of the protecting group R 8 of the lipoxyl group of the compound (VII).
- reaction can be carried out in the same manner as in the reaction of (VIII) with the compound (II) or a reactive derivative thereof.
- reaction of compound (XLVIII) with carbon dioxide to give compound (XLIX) The reaction can be carried out in the same manner as in the reaction for treating compound (II) with carbon dioxide to obtain compound (XII).
- reaction for obtaining compound (L) by reacting compound (III) with compound (XLIX) was carried out in the same manner as the reaction for obtaining compound (IV) by reacting compound (II) with compound (III). can do.
- reaction of compound (L) with compound (IX) or a salt thereof or a reactive derivative thereof to obtain compound (LI) is carried out by reacting compound (IX) or a reactive derivative thereof with compound (VIII).
- the reaction can be carried out in the same manner as in the reaction for obtaining the compound (I-a).
- the halogenation of compound (L) can be carried out by a conventional method.
- reaction of obtaining the compound (LIII) by reacting the compound (LII) with the compound (LI) should be carried out in the same manner as the reaction of obtaining the compound (IV) by reacting the compound (III) with the compound (III). Can be.
- reaction of oxidizing compound (LIII) and then reacting compound (VI) or a salt thereof to obtain compound (I) is performed by oxidizing compound (IV) to compound (V) and then compound (VI) or a salt thereof. Can be carried out in the same manner as in the reaction to obtain compound (I).
- reaction for protecting the carboxyl group of compound (L) can be carried out in the same manner as the above-mentioned reaction for protecting the carboxyl group of compound (XII) to obtain compound (XIII).
- a Halogen resin such as a benzyl or phenacyl halogenated resin can be used.
- reaction of reacting compound ( ⁇ ) with compound (LIV) is carried out by reacting compound (II) with compound
- reaction can be carried out in the same manner as in the reaction for acting (III).
- subsequent reaction with the compound (IX) or a reactive derivative thereof can be carried out in the same manner as in the reaction of the compound (VIII) with the compound (II) or the reactive derivative.
- the reaction of reacting compound (LVI) with compound (LV) to give compound (LVII) can be carried out in a solvent in the presence or absence of a deoxidizing agent.
- a deoxidizing agent include organic bases such as N, N-diisopropylethylamine, N-methylmorpholine, triethylamine, pyridine, N, N-dimethylaminopyridine, sodium hydroxide, sodium carbonate, sodium carbonate, and carbonic acid.
- An inorganic base such as thorium can be suitably used.
- any solvent that does not inhibit the reaction such as xylene, 'N, N-dimethyl / reformamide, tetrahydrofuran, dimethoxyethane, dimethylsulfoxide, and toluene, can be suitably used.
- This reaction suitably proceeds at 110 ° C to room temperature, particularly at o ° c to room temperature.
- the reaction of reacting compound (LII) with compound (LVII) to give compound (LIII) is carried out in the same manner as the reaction of reacting compound (III) with compound (III) to give compound (IV). Can be.
- the reaction can be carried out in the same manner as in the reaction with (VI).
- reaction After reacting compound (VI) with compound (LV), compound (LII) is reacted with compound (V) and compound (VI), and compound (LI) with compound (LII).
- the reaction can be carried out in the same manner as the reaction to be effected.
- reaction of treating compound (LVIII) with carbon dioxide to give compound (LIX) can be carried out in the same manner as the reaction of treating compound (XI) with carbon dioxide to give compound (XII).
- reaction of reacting compound (LVI) with compound (LIX) can be carried out in the same manner as the reaction of reacting compound (LVI) with compound (LV) to give compound (LVII).
- reaction for obtaining compound (LX) by reacting compound (IX) or a salt thereof can be carried out in the same manner as the reaction for obtaining compound (I) by reacting compound (IX) with compound (VIII). it can.
- reaction of reacting compound (LII) on compound (LX) to give compound (LXI) is carried out in the same manner as the reaction of reacting compound (LII) on compound (LI) to give compound (LIII). be able to.
- reaction of reacting compound (LXI) with compound (VI) or a salt thereof is as described in compound (V) above.
- the reaction can be carried out in the same manner as in the reaction of reacting compound (VI) with compound (VII) to obtain compound (VII).
- reaction of oxidizing the obtained compound can be carried out in the same manner as the reaction of oxidizing compound (IV).
- reaction of obtaining the compound (Id) by reacting the compound (III) on the obtained compound is carried out in the same manner as the reaction of obtaining the compound (VII) by reacting the compound (VI) with the compound (V). Can be applied.
- the reaction for protecting the compound (LXII) to obtain the compound (LXIII) is performed in the same manner as the reaction for obtaining the compound (IV) by reacting the compound (II) with the compound (III).
- the protecting group for example, a lower alkyl group which may be substituted may be used.
- reaction for obtaining LXI can be carried out in the same manner as the reaction for obtaining compound (I) by reacting compound (VIII) with compound (IX) or a reactive derivative thereof.
- reaction of deprotecting compound (LXIV) to obtain compound (LXV) can be carried out in the same manner as the reaction of deprotecting compound (XXXVI) to obtain compound (XXXVII).
- the reaction of reacting compound (LXVI) with compound (LXV) to give compound (LXVII) can be carried out in a solvent in the presence or absence of a base.
- a base include organic bases such as ⁇ , ⁇ -diisopropylethylamine, ⁇ -methylmorpholine, triethylamine, pyridine, ⁇ , ⁇ -dimethylaminopyridine, sodium hydroxide, sodium carbonate, potassium carbonate, carbonated carbonate.
- An inorganic base such as hydrogen sodium can be preferably used.
- any solvent that does not inhibit the reaction such as methanol, ethanol, acetone, ⁇ , ⁇ -dimethylformamide, and tetrahydrofuran, can be suitably used.
- the present reaction suitably proceeds at 110 ° C to 100 ° C, particularly preferably at 60 ° C to 70 ° C.
- reaction of reacting compound (XLVI) with compound (LXVII) can be carried out in the same manner as in the reaction of compound (XLV) with compound (XLVI).
- the compound (I) obtained by force is optionally converted to a pharmaceutically acceptable salt thereof.
- the starting compound (II) can be produced, for example, according to the method described in Journal Op'American * Chemical Society, p. 350, 65, 1943.
- Example 1 Specific examples (examples) of the compound (I) of the present invention synthesized by each of the above exemplified methods are shown below, but the present invention is not limited thereto.
- Example 1 Specific examples (examples) of the compound (I) of the present invention synthesized by each of the above exemplified methods are shown below, but the present invention is not limited thereto.
- 2-methyl-5- (3,4,5-trimethoxyphenylcanoleponinole) obtained in Example 11- (3) at room temperature was prepared by adding a solution of 100 mg of 2-methylaminoethanol in 1 ml of dimethylformamide at room temperature. To a solution of 120 mg of 1- (4-methyl-4-methoxybenzinoleamino) pyrimidine in 1 ml of dimethylformamide. The reaction mixture is stirred for 1 hour at room temperature and 50 ml of water are added.
- Example 1 The compounds obtained in Examples 1 to (3) and the corresponding starting materials are treated in the same manner as in Example (4) or Example 2 to obtain the compounds shown in Table 1 below.
- Example 1- (2) The compounds obtained in Example 1- (2) and the corresponding starting materials are treated in the same manner as in Example 11 (3) and Example 11 (4) to obtain the compounds shown in Table 2 below. .
- a mixture of 0.521 g and 20 ml of tetrahydrofuran is stirred at room temperature for 20 minutes to obtain a suspension.
- the suspension is added dropwise to a solution of 4.90 g of the compound obtained in (1) above in 25 ml of tetrahydrofuran over 10 minutes under ice-cooling, and the mixture is stirred at the same temperature for 1 hour.
- Example 68 2- (2-Pyridylmethoxy) -1-5-carboxy-41- (3-chloro-4-methoxypendinoleamino) pyrimidine 1O Omg 2-hydroxymethylpyrimidine 30 mg obtained by (3) A mixture of 53 mg of dimethylaminopropyl) -1-ethylcarbodiimide hydrochloride and 33 mg of dimethylaminopyridine in 3 ml of dimethylformamide is stirred at room temperature for 2 hours. Pour the reaction mixture into water and extract with ethyl acetate. The organic layer is washed with brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure.
- Example 70 2- (2-pyridylmethoxy) -1-5-canolepoxy-14- (3-chloro-4-methoxybenzinoleamino) pyrimidine 13 Omg obtained in Example 68- (3), methylene chloride 6 ml A mixture of 0.1 ml of thioyl chloride is stirred at room temperature for 1 hour. The volatiles are removed under reduced pressure, methylene chloride is further added, azeotropic distillation is performed under reduced pressure, and the mixture is diluted with 3 ml of methylene chloride.
- Example 68 A solution of 10 mg of 2- (2-pyridylmethoxy) -l-5-carboxy-l-l- (3-chloro-l-methoxybenzylamino) pyrimidine obtained in (3) in 3.5 ml of a methylene chloride 3.5 ml solution was added. 0.02 ml of thioyl chloride is added at room temperature, and the reaction mixture is stirred at room temperature for 1 hour. Volatiles were removed under reduced pressure at room temperature and more methylene chloride The mixture is azeotropically distilled under reduced pressure.
- the obtained residue is suspended in methylene chloride (8 ml), and the mixture is stirred with ice cooling to a mixture of 29 mg of N-methylmethoxyamine hydrochloride and a saturated aqueous solution of sodium hydrogen carbonate (3 ml). The reaction mixture is stirred at room temperature for 1 hour.
- Example 68 The compound obtained in (3) and the corresponding starting material were treated in the same manner as in Example 6970 to obtain the compounds shown in Table 3 below.
- Example 68 The compound obtained in (1) was dissolved in 40 ml of tetrahydrofuran, and a solution of 1.50 g of L-prolinol and 1.60 g of triethylamine in 10 ml of tetrahydrofuran was added at room temperature. After stirring for 1 hour, the reaction mixture is diluted with ethyl acetate, washed with an aqueous solution of sodium hydrogen carbonate and brine, and the organic layer is dried over anhydrous sodium sulfate.
- Example 84 A solution of 2-methylthio-14- (3-chloro-4-methoxybenzylamino) -15-forminolepirimidine l.OO g obtained in (2) in 10 ml of tetrahydrofuran at 178 ° C. Into the solution with a syringe to obtain a yellow suspension. This is stirred at the same temperature for 30 minutes.
- reaction solution is stirred at 178 ° C for 5 minutes, and then a saturated aqueous solution of sodium hydrogen carbonate is added.
- the mixture was extracted with ethyl acetate, and the organic layer was washed successively with water and brine, dried over sodium sulfate, and concentrated under reduced pressure to give a yellow oil.
- Example 87 The compound obtained in Example 88, 124. Omg, was added in the same manner as in Example 87.
- reaction mixture is poured into a 10% aqueous solution of citric acid under ice-cooling, the organic layer is separated, washed with water and brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure.
- Example 68 2- (methylsulfinyl) -14- (3-chloro-4- (methoxypentinoleamino) -1-5-ethoxycarbonylpyrimidine obtained in (1)
- hydrofuran (6 ml) was added dropwise 2 N sodium hydroxide (1.32 ml) under ice-cooling over 2 minutes under ice-cooling, and the reaction mixture was stirred for 30 minutes under ice-cooling.
- 8 ml of tetrahydrofuran and 6 ml of ⁇ , ⁇ -dimethylacetoamide are added, and the reaction mixture is stirred for 30 minutes under ice cooling.
- the first fraction was concentrated under reduced pressure, and 33 mg of a slightly brown oily substance, 2-methylthio-1- (3-chloro-1--4-methoxypentinoleamino) -15-ethoxycarpulpyrimidine, was added. obtain.
- reaction mixture is neutralized with a 10% aqueous solution of citric acid, and tetrahydrofuran and ethanol are distilled off under reduced pressure. The resulting precipitate is collected and washed with water to give a colorless powder.
- the powder is dissolved in a mixture of 10% sodium hydroxide monoethyl acetate, and the aqueous layer is separated and washed with ethyl acetate.
- Anhydrous tetrahydrofuran consisting of 356 mg of 2-chloro-1,4- (3-chloro-4-4-methoxybenzizoleamino) -1-5-ethoxycarbylpyrimidine (compound obtained in Example 95) and 109 mg of 2-hydroxymethylpyridine 4 Add 12 mg of potassium t-butoxide to a 5 ml solution under ice-cooling and stir for 30 minutes.
- the collected organic layer is washed with water and a saturated aqueous solution of sodium chloride, dried over sodium sulfate, and concentrated under reduced pressure.
- the solvent is distilled off under reduced pressure, and the residue is diluted with water.
- the mixture is washed with a mixed solvent of isopropyl ether and ethyl acetate (1: 1), and the organic layer is extracted with 10% hydrochloric acid.
- the collected aqueous layer is washed with a mixed solvent of isopropyl ether / ethyl acetate (2: 1), basified with 10% aqueous sodium hydroxide solution, and extracted twice with ethyl acetate.
- Example 287 The corresponding starting material is worked up as in Example 287 to give the compounds listed in Table 7 below.
- Example 297 2-Methoxycarbonyl 3- (3-chloro-1-4-methoxybenzylidamino) -1-5-chlorovirazine obtained in (3) was added to a solution of 7 lmg of 5-chlorovirazine and 25 mg of 2-hydroxymethylpyridine in 3 ml of tetrahydrofuran. 26 mg of potassium t-butoxide are added under water cooling. The mixture is stirred at the same temperature for 30 minutes. Dilute the reaction mixture with 10% aqueous citric acid and extract with ethyl acetate. The extract is washed with water and saturated saline, dried over anhydrous sodium sulfate, and then concentrated under reduced pressure.
- Residue Is purified by silica gel column chromatography (silica gel 5 g, solvent; solvent form: ethyl acetate 3: 1), separated, crystallized with isopropyl ether, and the light yellow crystalline powder of 2-methoxycarbonyl 3 — (3-Chloro-4-methoxybenzylamino) -1-5- (2-pyridylmethoxy) virazine (25 mg) is obtained. Melting point: 132-133 ° (:, MS (m / z): 415 (M + H) + Example 299
- Example 304 The corresponding starting material is worked up as in Example 304 to give the compounds shown in Table 11 below.
- Example 307 The corresponding starting material is worked up as in Example 307 to give the compounds shown in Table 12 below.
- a mixture of 4 g and 170 ml of getyl ether is stirred at room temperature for 15 hours.
- the solvent is distilled off under reduced pressure, and the pale yellow solid residue is diluted with a mixed solvent of 170 ml of acetic acid and 17 ml of water, and the mixture is refluxed for 9.5 hours.
- the solvent was distilled off under reduced pressure, and the residue was mixed with 50 g of silica gel using a mixed solvent of chloroform and methanol (1: 1).
- Example 310 The corresponding starting material is worked up as in Example 310 to give the compounds shown in Table 13 below.
- Aqueous sodium bicarbonate solution is added to the reaction mixture, and the mixture is extracted with ethyl acetate. The organic layer is washed, dried, and the solvent is distilled off under reduced pressure. Crystallization from ether yields 55 mg of 5-promo 3- (3-chloro-1-4-methoxybenzylidamino) -12- (2-pyrimidylmethylaminocarbonyl) pyridine as pale yellow crystals. Melting point: 179-183 ° C (decomposition).
- Example 317 In the same manner as in Example 316 (5) and (6) above, 3- (3-chloro-3-methoxybenzylamino) pyridine-12-carboxylic acid was converted to 3- (3-3-chloro-1-hydroxy) -Methoxybenzylamino) 1- (2-hydroxymethinol-1-pyrrolidinyl) -2- (21-morpholini / reethylaminocarbonyl) pyridine is obtained. MS (/ z): 505 (M + H) +.
- reaction mixture is diluted with a 10% aqueous solution of citric acid to which ice has been added, and extracted with ethyl acetate.
- the extract layers were combined, washed with water and saturated saline, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give a light brown crystalline powder as 4- (3-chlorobenzyl-4-methoxybenzylamino). 2.92 g of 1,2,6-dichloropyrimidine-15-carboxylic acid are obtained. Melting point: 144-151 ° C
- reaction mixture is acidified with 10% hydrochloric acid, diluted with water and extracted with ethyl acetate. The organic layer is washed, dried and concentrated in vacuo. The obtained solid is triturated with hexane to obtain 10.42 g of 4,6-dichloro-15-carboxy-2-methinorethiopyrimidine as a slightly brown crystalline powder. Melting point: 151-158 ° C (decomposition)
- the organic layer is extracted with a 10% aqueous solution of citric acid, the aqueous layer is made basic with sodium hydrogen carbonate, and extracted with ethyl acetate.
- the ethyl acetate layer is washed, dried and concentrated in vacuo.
- 6- (4-Hydroxypiperidine-1-1-yl) 1-2-clopyrimidine 617m get g.
- reaction mixture is diluted with aqueous citric acid, made basic with saturated aqueous sodium hydrogen carbonate and extracted with ethyl acetate.
- the organic layer is washed, dried and concentrated in vacuo to give a pale yellow powder of 4- (3-chloro-1--4-methoxybenzylamino) -15-methoxycarbonyl-16- (5,6,7 ,
- Example 326 4- (3-chloro-1-4-methoxybenzylamine) obtained in (4) 15- [2- (4-Resin methoxy-3-propomophenyl) ethoxyproponyl] —6— Chloro-2-methylthiopyrimidine and the corresponding starting compound were subjected to the same operation as in Example 321 (3), namely, the suspension of the compound was suspended in dimethylformamide, and 3 equivalents of triethylamine and 3 equivalents of RH were added. (Amines described in Table 16 below) and shaken at room temperature for 16 hours.
- the resin is separated by filtration, washed several times with dimethylformamide, hydrated dimethylformamide (50%), water, methanol, tetrahydrofuran, and isopropyl ether, and dried under reduced pressure to obtain a compound described in Table 16 below. Get.
- each of the resin compounds obtained in the above (1) was swelled by suspending the reacting resin in methylene chloride. 2,5 eq.) In methylene chloride and shake at room temperature for 16 hours. The resin is filtered off, washed with methylene chloride, dimethylacetamide, methanol and isopropyl ether several times, and dried under reduced pressure to obtain the compounds shown in Table 17 below.
- Example 321 (6) The compound obtained in the above (3) was suspended in the same manner as in Example 321 (6), that is, the resin to be reacted was suspended in tetrahydrofuran, and 10 equivalents of a sodium methoxide / methanol solution was added thereto. Stir at 2.5 C for 2.5 hours. After cooling, add a 10% aqueous solution of citric acid to each reaction solution, neutralize with aqueous sodium bicarbonate, and extract with ethyl acetate. The organic layer is washed with a saturated saline solution and dried over anhydrous magnesium sulfate. After each concentration under reduced pressure, the residue was purified using silica gel column chromatography and preparative thin-layer silica gel, etc. to give the following compound represented by the following 19th formula: Compounds of Examples 332-4, 334-4, and 335-4 Get.
- Example 326 4- (3-chloro-1--4-methoxybenzylamino) -15- [2- (4-methoxy-4-methoxyphenyl) ethoxycanoleponyl] -6-chloro-obtained in Example 326 (4) above 2-Methylthiopyrimidine and the corresponding starting compound (RiH) were treated in the same manner as in Examples 327 to 335 (1) to (4) above, and the compounds described in Table 20 below, the compounds of Example 340 and Example 341 were obtained. Get.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001241142A AU2001241142B2 (en) | 2000-04-28 | 2001-03-15 | Cyclic compounds |
CA002407231A CA2407231A1 (en) | 2000-04-28 | 2001-03-15 | Cyclic compounds |
US10/258,545 US7220736B2 (en) | 2000-04-28 | 2001-03-15 | Pyrimidine compounds |
MXPA02010693A MXPA02010693A (es) | 2000-04-28 | 2001-03-15 | Compuestos ciclicos. |
NZ522217A NZ522217A (en) | 2000-04-28 | 2001-03-15 | Cyclic compounds |
AU4114201A AU4114201A (en) | 2000-04-28 | 2001-03-15 | Cyclic compounds |
EP01912373A EP1277741A4 (en) | 2000-04-28 | 2001-03-15 | CYCLE CONNECTIONS |
US10/699,804 US7273868B2 (en) | 2000-04-28 | 2003-11-04 | Pyrazine derivatives |
US11/889,749 US20080027037A1 (en) | 2000-04-28 | 2007-08-16 | Cyclic compounds |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000130371 | 2000-04-28 | ||
JP2000-130371 | 2000-04-28 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/258,545 A-371-Of-International US7220736B2 (en) | 2000-04-28 | 2001-03-15 | Pyrimidine compounds |
US10258545 A-371-Of-International | 2001-03-15 | ||
US10/699,804 Continuation-In-Part US7273868B2 (en) | 2000-04-28 | 2003-11-04 | Pyrazine derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001083460A1 true WO2001083460A1 (fr) | 2001-11-08 |
Family
ID=18639494
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/002034 WO2001083460A1 (fr) | 2000-04-28 | 2001-03-15 | Composes cycliques |
Country Status (9)
Country | Link |
---|---|
US (1) | US7220736B2 (ja) |
EP (1) | EP1277741A4 (ja) |
KR (1) | KR100711042B1 (ja) |
CN (2) | CN1440393A (ja) |
AU (2) | AU2001241142B2 (ja) |
CA (1) | CA2407231A1 (ja) |
MX (1) | MXPA02010693A (ja) |
NZ (1) | NZ522217A (ja) |
WO (1) | WO2001083460A1 (ja) |
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003020278A1 (en) * | 2001-08-30 | 2003-03-13 | Novartis Ag | Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases |
WO2003032994A3 (de) * | 2001-10-17 | 2003-06-12 | Boehringer Ingelheim Pharma | 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren |
EP1321463A1 (en) * | 2001-12-21 | 2003-06-25 | Shire Biochem Inc. | Thiazole derivatives and their use for the treatment or prevention of Flavivirus infections |
US7067539B2 (en) | 2001-02-08 | 2006-06-27 | Schering Corporation | Cannabinoid receptor ligands |
US7071213B2 (en) | 2001-11-14 | 2006-07-04 | Schering Corporation | Cannabinoid receptor ligands |
WO2006123639A1 (ja) * | 2005-05-18 | 2006-11-23 | Asahi Kasei Pharma Corporation | ピリミジン誘導体 |
US7217732B2 (en) | 2002-06-19 | 2007-05-15 | Schering Corporation | Cannabinoid receptor agonists |
JP2008508309A (ja) * | 2004-07-30 | 2008-03-21 | アボット・ラボラトリーズ | ピリドンカルボン酸抗菌薬の調製 |
US7452886B2 (en) | 2001-08-30 | 2008-11-18 | Novartis Ag | Pyrrolo pyrimidines as agents for the inhibition of cystein proteases |
WO2009051112A1 (ja) | 2007-10-15 | 2009-04-23 | Takeda Pharmaceutical Company Limited | アミド化合物およびその用途 |
US7592343B2 (en) | 2004-09-20 | 2009-09-22 | Xenon Pharmaceuticals Inc. | Pyridazine-piperazine compounds and their use as stearoyl-CoA desaturase inhibitors |
US7642272B2 (en) | 2003-03-20 | 2010-01-05 | Schering Corporation | Cannabinoid receptor ligands |
US7659394B2 (en) | 2004-04-30 | 2010-02-09 | Pfizer Inc | Substituted morpholine compounds for the treatment of central nervous system disorders |
US7767677B2 (en) | 2004-09-20 | 2010-08-03 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
US7777036B2 (en) | 2004-09-20 | 2010-08-17 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as therapeutic agents |
US7829712B2 (en) | 2004-09-20 | 2010-11-09 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase |
US7919496B2 (en) | 2004-09-20 | 2011-04-05 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes |
SG170614A1 (en) * | 2002-06-20 | 2011-05-30 | Vertex Pharma | Processes for preparing substituted pyrimidines and pyrimidine derivatives as inhibitors of protein kinase |
US7951805B2 (en) | 2004-09-20 | 2011-05-31 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase |
US7998954B2 (en) | 2007-05-31 | 2011-08-16 | Kyowa Hakko Kirin Co., Ltd. | Pyrimidodiazepinone derivative |
US8071603B2 (en) | 2004-09-20 | 2011-12-06 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
US8299254B2 (en) | 2004-07-30 | 2012-10-30 | Abbott Laboratories | Preparation of pyridonecarboxylic acid antibacterials |
US8338420B1 (en) | 2002-12-04 | 2012-12-25 | Mitsubishi Tanabe Pharma Corporation | Treatment of Parkinson's disease and enhancement of dopamine signal using PDE 10 inhibitor |
US8519158B2 (en) * | 2004-03-12 | 2013-08-27 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds and methods |
US8541457B2 (en) | 2005-06-03 | 2013-09-24 | Xenon Pharmaceuticals Inc. | Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors |
JP2014522859A (ja) * | 2011-07-21 | 2014-09-08 | シュエンジュウ・ファーマ・カンパニー・リミテッド | 複素環置換ピリミジン化合物 |
WO2014187273A1 (zh) * | 2013-05-23 | 2014-11-27 | 苏州明锐医药科技有限公司 | 阿伐那非的制备方法 |
JP2015516429A (ja) * | 2012-05-08 | 2015-06-11 | アンヴィル エルエルシー | アルファ7ニコチン性アセチルコリン受容体アロステリック調節因子、それらの誘導体およびその使用 |
JP2015517574A (ja) * | 2012-05-22 | 2015-06-22 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | がん治療のためのピリミジン化合物 |
JP2015524828A (ja) * | 2012-08-14 | 2015-08-27 | シュエンジュウ・ファーマ・カンパニー・リミテッド | 二環性基置換ピリミジン化合物 |
US10906888B2 (en) | 2016-07-14 | 2021-02-02 | Pfizer Inc. | Pyrimidine carboxamides as inhibitors of Vanin-1 enzyme |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4460292B2 (ja) * | 2001-10-17 | 2010-05-12 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | ピリミジン誘導体、これらの化合物を含む医薬組成物、その使用及びその調製方法 |
US20050119251A1 (en) * | 2001-12-21 | 2005-06-02 | Jian-Min Fu | Nicotinamide derivatives and their use as therapeutic agents |
US7176310B1 (en) * | 2002-04-09 | 2007-02-13 | Ucb Sa | Pyrimidinecarboxamide derivatives and their use as anti-inflammatory agents |
EP1575940B1 (en) | 2002-11-21 | 2011-10-05 | Novartis AG | 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer |
US7504396B2 (en) | 2003-06-24 | 2009-03-17 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
US7932270B2 (en) * | 2006-08-01 | 2011-04-26 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
US7919511B2 (en) * | 2006-08-01 | 2011-04-05 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
US7939534B2 (en) * | 2006-08-01 | 2011-05-10 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
US7939548B2 (en) * | 2006-08-02 | 2011-05-10 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
JP2010518107A (ja) | 2007-02-06 | 2010-05-27 | ノバルティス アーゲー | Pi3−キナーゼ阻害剤およびその使用方法 |
US20090198057A1 (en) * | 2008-02-05 | 2009-08-06 | Pu-Ping Lu | Certain Chemical Entities, Compositions, and Methods |
CN102372697A (zh) * | 2010-08-19 | 2012-03-14 | 山东轩竹医药科技有限公司 | 取代的嘧啶类化合物 |
US9168259B2 (en) * | 2010-10-20 | 2015-10-27 | Grünenthal GmbH | Substituted 6-amino-nicotinamides as KCNQ2/3 modulators |
SG11201400989TA (en) | 2011-09-27 | 2014-04-28 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
UY34632A (es) | 2012-02-24 | 2013-05-31 | Novartis Ag | Compuestos de oxazolidin- 2- ona y usos de los mismos |
US9296733B2 (en) | 2012-11-12 | 2016-03-29 | Novartis Ag | Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases |
SG11201507063YA (en) | 2013-03-14 | 2015-10-29 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
BR112015025033B1 (pt) * | 2013-03-29 | 2022-04-19 | Xuanzhu Pharma Co., Ltd | Composto e seu uso como inibidor de pde-5, bem como preparação farmacêutica compreeendendo o dito composto |
CN103254179B (zh) * | 2013-05-23 | 2014-09-10 | 苏州明锐医药科技有限公司 | 阿伐那非的制备方法 |
CN103483323B (zh) * | 2013-08-23 | 2016-01-20 | 苏州永健生物医药有限公司 | 艾瓦那非 |
CA2945128A1 (en) * | 2014-04-11 | 2015-10-15 | The University Of North Carolina At Chapel Hill | Mertk-specific pyrimidine compounds |
CN104356115B (zh) * | 2014-11-21 | 2016-08-24 | 齐鲁天和惠世制药有限公司 | 一种4-[(3-氯-4-甲氧基苄基)氨基]-2-[2-(羟甲基)-1-吡咯烷基]嘧啶-5-羧酸乙酯的制备方法 |
CN105439964B (zh) * | 2015-12-09 | 2019-02-15 | 河北大学 | 一种阿伐那非中间体的制备方法 |
CN107879986A (zh) * | 2017-12-20 | 2018-04-06 | 重庆英斯凯化工有限公司 | 一种阿伐那非杂质的合成方法 |
CN109280049B (zh) * | 2018-09-25 | 2021-02-02 | 重庆奥舍生物化工有限公司 | 一种医药化合物阿伐那非的合成方法 |
GB202215290D0 (en) * | 2022-10-17 | 2022-11-30 | Univ Durham | Treatment of leishmaniasis |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3560624A (en) * | 1968-10-18 | 1971-02-02 | Merck & Co Inc | Anticoccidial 2-alkylamino-4-amino benzoic acids |
JPS5095273A (ja) * | 1973-12-24 | 1975-07-29 | ||
EP0103218A1 (de) * | 1982-09-02 | 1984-03-21 | Hoechst Aktiengesellschaft | 10-Phenyl-1,3,9-triazaanthracene und diese enthaltendes photopolymerisierbares Gemisch |
WO1995006648A1 (en) * | 1993-09-03 | 1995-03-09 | Kyowa Hakko Kogyo Co., Ltd. | Imidazoquinazoline derivative |
WO1996022991A1 (en) * | 1995-01-27 | 1996-08-01 | Abbott Laboratories | Bicyclic substituted hexahydrobenz[e]isoindole alpha-1- adrenergic antagonists |
JP2000026294A (ja) * | 1998-05-07 | 2000-01-25 | Sankyo Co Ltd | アリ―ルウレア又はアリ―ルメチルカルバモイル誘導体を含有する医薬 |
WO2000076980A1 (fr) * | 1999-06-10 | 2000-12-21 | Yamanouchi Pharmaceutical Co., Ltd. | Nouveaux derives heterocycliques azotes ou leurs sels |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5481299A (en) | 1977-12-09 | 1979-06-28 | Daito Koeki Kk | Preparation of 2,8-disubstituted-6-formyl-5,8-dihydro-5- oxopyrido 2,3-d pyrimidine derivative |
AT392789B (de) * | 1985-01-23 | 1991-06-10 | Toyama Chemical Co Ltd | Verfahren zur herstellung von 1-substituierten aryl-1,4-dihydro-4-oxonaphthyridinderivaten |
GB9012316D0 (en) | 1990-06-01 | 1990-07-18 | Wellcome Found | Pharmacologically active cns compounds |
GB9311920D0 (en) | 1993-06-09 | 1993-07-28 | Pfizer Ltd | Therapeutic agents |
AU694465B2 (en) | 1993-12-27 | 1998-07-23 | Eisai Co. Ltd. | Anthranilic acid derivative |
CN1151136C (zh) | 1994-08-09 | 2004-05-26 | 卫材株式会社 | 缩合哒嗪系化合物 |
KR100239800B1 (ko) | 1996-11-28 | 2000-03-02 | 손경식 | 4,5-디아미노 피리미딘 유도체 및 이의 제조방법 |
US6683783B1 (en) * | 1997-03-07 | 2004-01-27 | William Marsh Rice University | Carbon fibers formed from single-wall carbon nanotubes |
ES2308821T3 (es) * | 1997-12-15 | 2008-12-01 | Astellas Pharma Inc. | Nuevos derivados de pirimidin-5-carboxamida. |
IL132406A0 (en) | 1998-10-21 | 2001-03-19 | Pfizer Prod Inc | Treatment of bph with cgmp elevators |
GB9823101D0 (en) | 1998-10-23 | 1998-12-16 | Pfizer Ltd | Pharmaceutically active compounds |
KR100532546B1 (ko) | 1999-09-16 | 2005-12-01 | 다나베 세이야꾸 가부시키가이샤 | 방향족 질소 함유 6-원 고리 화합물 |
-
2001
- 2001-03-15 EP EP01912373A patent/EP1277741A4/en not_active Withdrawn
- 2001-03-15 KR KR1020027014520A patent/KR100711042B1/ko not_active Expired - Fee Related
- 2001-03-15 AU AU2001241142A patent/AU2001241142B2/en not_active Ceased
- 2001-03-15 CN CN01811790A patent/CN1440393A/zh active Pending
- 2001-03-15 AU AU4114201A patent/AU4114201A/xx active Pending
- 2001-03-15 MX MXPA02010693A patent/MXPA02010693A/es active IP Right Grant
- 2001-03-15 US US10/258,545 patent/US7220736B2/en not_active Expired - Fee Related
- 2001-03-15 WO PCT/JP2001/002034 patent/WO2001083460A1/ja active IP Right Grant
- 2001-03-15 CN CN2004100980985A patent/CN1657523A/zh active Pending
- 2001-03-15 CA CA002407231A patent/CA2407231A1/en not_active Abandoned
- 2001-03-15 NZ NZ522217A patent/NZ522217A/en unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3560624A (en) * | 1968-10-18 | 1971-02-02 | Merck & Co Inc | Anticoccidial 2-alkylamino-4-amino benzoic acids |
JPS5095273A (ja) * | 1973-12-24 | 1975-07-29 | ||
EP0103218A1 (de) * | 1982-09-02 | 1984-03-21 | Hoechst Aktiengesellschaft | 10-Phenyl-1,3,9-triazaanthracene und diese enthaltendes photopolymerisierbares Gemisch |
WO1995006648A1 (en) * | 1993-09-03 | 1995-03-09 | Kyowa Hakko Kogyo Co., Ltd. | Imidazoquinazoline derivative |
WO1996022991A1 (en) * | 1995-01-27 | 1996-08-01 | Abbott Laboratories | Bicyclic substituted hexahydrobenz[e]isoindole alpha-1- adrenergic antagonists |
JP2000026294A (ja) * | 1998-05-07 | 2000-01-25 | Sankyo Co Ltd | アリ―ルウレア又はアリ―ルメチルカルバモイル誘導体を含有する医薬 |
WO2000076980A1 (fr) * | 1999-06-10 | 2000-12-21 | Yamanouchi Pharmaceutical Co., Ltd. | Nouveaux derives heterocycliques azotes ou leurs sels |
Non-Patent Citations (6)
Title |
---|
CHAN REBECCA L., BRUICE THOMAS C.: "The chemistry of an electron-deficient 5-deazaflavin. 8-Cyano-10-methyl-5-deazaisoalloxazine", J. AM. CHEM. SOC., vol. 99, no. 20, 1977, pages 6721 - 6730, XP002941483 * |
HIRAI KENTARO, SUGIMOTO HIROHIKO, ISHIBA TERUYUKI: "Heterocyclic cation systems. 14. Synthesis of thieno(3,2-e)(1,4)diazepine, thiazolo(4,5-e)(1,4)diazepine and s-triazolo(3,4-c)thiazolo(4,5-e)(1,4)diazepine derivatives", J. ORG. CHEM., vol. 45, no. 2, 1980, pages 253 - 260, XP002941486 * |
KIM DONG CHAN ET AL.: "Synthesis of new pyrrolidine C-nucleosides via Staudinger-aza-Wittig cyclization of .gamma.-azido ketone", TETRAHEDRON LETT., vol. 40, no. 26, 1999, pages 4825 - 4828, XP002941484 * |
MERTES MATHIAS P., ZIELINSKI JAMES, PILLAR CONRAD: "Approaches to the synthesis of 1-deazauridine and 2'-deoxy-1-deazauridine", J. MED. CHEM., vol. 10, no. 2, 1967, pages 320 - 325, XP002941485 * |
See also references of EP1277741A4 * |
VAN AARDT THEUNIS G., VAN RENSBURG HENDRIK, FERREIRA DANEEL: "Direct synthesis of pterocarpans via aldol condensation of phenylacetates with benzaldehydes", TETRAHEDRON, vol. 55, no. 40, 1999, pages 11773 - 11786, XP002941482 * |
Cited By (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7067539B2 (en) | 2001-02-08 | 2006-06-27 | Schering Corporation | Cannabinoid receptor ligands |
US7112589B2 (en) | 2001-08-30 | 2006-09-26 | Novartis Ag | Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases |
WO2003020278A1 (en) * | 2001-08-30 | 2003-03-13 | Novartis Ag | Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases |
US7452886B2 (en) | 2001-08-30 | 2008-11-18 | Novartis Ag | Pyrrolo pyrimidines as agents for the inhibition of cystein proteases |
AU2002333758B2 (en) * | 2001-08-30 | 2006-01-19 | Novartis Ag | Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin K inhibitory activity for the treatment of inflammations and other diseases |
WO2003032994A3 (de) * | 2001-10-17 | 2003-06-12 | Boehringer Ingelheim Pharma | 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren |
US7645774B2 (en) | 2001-11-14 | 2010-01-12 | Schering Corporation | Cannabinoid receptor ligands |
US7071213B2 (en) | 2001-11-14 | 2006-07-04 | Schering Corporation | Cannabinoid receptor ligands |
US6936629B2 (en) | 2001-12-21 | 2005-08-30 | Virochem Pharma Inc. | Compounds and methods for the treatment or prevention of flavivirus infections |
EP1321463A1 (en) * | 2001-12-21 | 2003-06-25 | Shire Biochem Inc. | Thiazole derivatives and their use for the treatment or prevention of Flavivirus infections |
US7217732B2 (en) | 2002-06-19 | 2007-05-15 | Schering Corporation | Cannabinoid receptor agonists |
SG170614A1 (en) * | 2002-06-20 | 2011-05-30 | Vertex Pharma | Processes for preparing substituted pyrimidines and pyrimidine derivatives as inhibitors of protein kinase |
US8338420B1 (en) | 2002-12-04 | 2012-12-25 | Mitsubishi Tanabe Pharma Corporation | Treatment of Parkinson's disease and enhancement of dopamine signal using PDE 10 inhibitor |
US7642272B2 (en) | 2003-03-20 | 2010-01-05 | Schering Corporation | Cannabinoid receptor ligands |
US9359285B2 (en) | 2004-03-12 | 2016-06-07 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds and methods |
US8865918B2 (en) | 2004-03-12 | 2014-10-21 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds and methods |
US8519158B2 (en) * | 2004-03-12 | 2013-08-27 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds and methods |
US7659394B2 (en) | 2004-04-30 | 2010-02-09 | Pfizer Inc | Substituted morpholine compounds for the treatment of central nervous system disorders |
JP2008508309A (ja) * | 2004-07-30 | 2008-03-21 | アボット・ラボラトリーズ | ピリドンカルボン酸抗菌薬の調製 |
US8299254B2 (en) | 2004-07-30 | 2012-10-30 | Abbott Laboratories | Preparation of pyridonecarboxylic acid antibacterials |
US8648196B2 (en) | 2004-07-30 | 2014-02-11 | Abbvie Inc. | Preparation of pyridonecarboxylic acid antibacterials |
US7919496B2 (en) | 2004-09-20 | 2011-04-05 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes |
US8026360B2 (en) | 2004-09-20 | 2011-09-27 | Xenon Pharmaceuticals Inc. | Substituted pyridazines as stearoyl-CoA desaturase inhibitors |
US8071603B2 (en) | 2004-09-20 | 2011-12-06 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
US7829712B2 (en) | 2004-09-20 | 2010-11-09 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase |
US7951805B2 (en) | 2004-09-20 | 2011-05-31 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase |
US7777036B2 (en) | 2004-09-20 | 2010-08-17 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as therapeutic agents |
US7767677B2 (en) | 2004-09-20 | 2010-08-03 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
US7592343B2 (en) | 2004-09-20 | 2009-09-22 | Xenon Pharmaceuticals Inc. | Pyridazine-piperazine compounds and their use as stearoyl-CoA desaturase inhibitors |
WO2006123639A1 (ja) * | 2005-05-18 | 2006-11-23 | Asahi Kasei Pharma Corporation | ピリミジン誘導体 |
US8541457B2 (en) | 2005-06-03 | 2013-09-24 | Xenon Pharmaceuticals Inc. | Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors |
US7998954B2 (en) | 2007-05-31 | 2011-08-16 | Kyowa Hakko Kirin Co., Ltd. | Pyrimidodiazepinone derivative |
JP5345931B2 (ja) * | 2007-05-31 | 2013-11-20 | 協和発酵キリン株式会社 | ピリミドジアゼピノン誘導体 |
US8329691B2 (en) | 2007-10-15 | 2012-12-11 | Takeda Pharmaceutical Company Limited | Amide compounds and use of the same |
WO2009051112A1 (ja) | 2007-10-15 | 2009-04-23 | Takeda Pharmaceutical Company Limited | アミド化合物およびその用途 |
JP5441705B2 (ja) * | 2007-10-15 | 2014-03-12 | 武田薬品工業株式会社 | アミド化合物およびその用途 |
JP2014522859A (ja) * | 2011-07-21 | 2014-09-08 | シュエンジュウ・ファーマ・カンパニー・リミテッド | 複素環置換ピリミジン化合物 |
JP2015516429A (ja) * | 2012-05-08 | 2015-06-11 | アンヴィル エルエルシー | アルファ7ニコチン性アセチルコリン受容体アロステリック調節因子、それらの誘導体およびその使用 |
JP2015517574A (ja) * | 2012-05-22 | 2015-06-22 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | がん治療のためのピリミジン化合物 |
JP2015524828A (ja) * | 2012-08-14 | 2015-08-27 | シュエンジュウ・ファーマ・カンパニー・リミテッド | 二環性基置換ピリミジン化合物 |
WO2014187273A1 (zh) * | 2013-05-23 | 2014-11-27 | 苏州明锐医药科技有限公司 | 阿伐那非的制备方法 |
US9453001B2 (en) | 2013-05-23 | 2016-09-27 | Suzhou Miracpharma Technology Co., Ltd. | Avanafil preparation method |
US10906888B2 (en) | 2016-07-14 | 2021-02-02 | Pfizer Inc. | Pyrimidine carboxamides as inhibitors of Vanin-1 enzyme |
Also Published As
Publication number | Publication date |
---|---|
KR20020093997A (ko) | 2002-12-16 |
US7220736B2 (en) | 2007-05-22 |
CN1657523A (zh) | 2005-08-24 |
AU4114201A (en) | 2001-11-12 |
EP1277741A4 (en) | 2003-05-07 |
US20030229089A1 (en) | 2003-12-11 |
MXPA02010693A (es) | 2003-03-10 |
CN1440393A (zh) | 2003-09-03 |
CA2407231A1 (en) | 2002-10-23 |
KR100711042B1 (ko) | 2007-04-24 |
NZ522217A (en) | 2004-04-30 |
AU2001241142B2 (en) | 2005-09-22 |
EP1277741A1 (en) | 2003-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001083460A1 (fr) | Composes cycliques | |
US7273868B2 (en) | Pyrazine derivatives | |
WO2001019802A1 (fr) | Composes cycliques aromatiques azotes a six elements | |
EP1756104B1 (en) | Tetrahydronaphthyridine derivatives useful as histamine h3 receptor ligands | |
JP4625838B2 (ja) | Hivインテグラーゼ阻害薬 | |
JP4166991B2 (ja) | ピリドピリミジンまたはナフチリジン誘導体 | |
JPH0794454B2 (ja) | ピラゾロピリジン化合物およびその製造法 | |
JP7434294B2 (ja) | キナーゼ阻害剤としてのインダゾールカルボキサミド | |
WO2001030779A1 (fr) | Derives de naphthyridine | |
WO1998023592A1 (fr) | Nouveaux derives d'acide pyridonecarboxylique ou leurs sels, et medicaments contenant ceux-ci en tant que principe actif | |
JP5113751B2 (ja) | p38キナーゼ阻害剤として有用な二環性複素環化合物 | |
US20080027037A1 (en) | Cyclic compounds | |
JP3637961B2 (ja) | 芳香族含窒素六員環化合物 | |
JP2004083587A (ja) | 医薬組成物 | |
AU658631B2 (en) | New hetaryloxy-beta-carbolines, their production and use in pharmaceutical agents | |
EP1556381B1 (en) | Pyrazole amides for treating hiv infections | |
JP4280165B2 (ja) | 水溶性フェニルピリダジン誘導体及びこれを含有する医薬 | |
JP2004002318A (ja) | 含窒素複素環化合物 | |
JP5243274B2 (ja) | 4型メラノコルチン受容体アゴニストのピペリジノイルピロリジン | |
AU2005203687A1 (en) | Cyclic compounds | |
WO2000012503A1 (fr) | Derives de naphthyridine et leur procede de preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2001 580889 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2407231 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 522217 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001912373 Country of ref document: EP Ref document number: 10258545 Country of ref document: US Ref document number: 2001241142 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2002/010693 Country of ref document: MX Ref document number: 1020027014520 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 1020027014520 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 018117902 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2001912373 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 522217 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 522217 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001241142 Country of ref document: AU |